CannTrust (CNTTQ) 40-F/A 5 Apr 19 2018 FY Annual report (Canada) (amended) Financial data

Document And Entity Information

Document And Entity Information	12 Months Ended
	Dec. 31, 2018shares
Document And Entity Information [Abstract]
Entity Registrant Name	CannTrust Holdings Inc.
Entity Central Index Key	0001652499
Trading Symbol	ctst
Entity Current Reporting Status	Yes
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding	105,608,486
Document Type	40-F
Document Period End Date	Dec. 31, 2018
Amendment Flag	false
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	FY
Entity Emerging Growth Company	true
Entity Ex Transition Period	false

Consolidated Statements of Fina

Consolidated Statements of Financial Position - CAD ($)		Dec. 31, 2018	Dec. 31, 2017
Current
Cash		$ 9,022,821	$ 17,961,043
Short term investments	[1]	63,023,908	201,538
Harmonized sales tax recoverable		1,492,110	2,636,710
Inventory		35,389,490	10,959,022
Biological assets		10,502,579	9,843,690
Accounts receivable		6,151,604	160,383
Prepaid expenses		2,859,039	2,465,506
Total current assets		128,441,551	44,227,892
Investments		10,661,932	156,073
Restricted cash	[2]	100,000	100,765
Property and equipment		62,208,905	33,963,685
Financial assets		901,350	0
Total Assets		202,313,738	78,448,415
Current
Accounts payable and accrued liabilities		12,806,458	6,579,997
Current portion of promissory note		200,000	200,000
Current portion of mortgage		3,790,610
Total current liabilities		16,797,068	6,779,997
Promissory note		600,000	800,000
Mortgage		9,457,876
Deferred tax		1,433,000
Total Liabilities		28,287,944	7,579,997
Shareholders' Equity
Share capital		207,061,423	104,824,215
Share-based payment reserve		8,714,188	2,272,302
Warrants reserve		11,393,687	3,361,789
Deficit		(53,143,504)	(39,589,888)
Total Shareholders' Equity		174,025,794	70,868,418
Total Liabilities and Shareholders' Equity		$ 202,313,738	$ 78,448,415
[1]	The investment is a one-year GIC, redeemable every 30 days, held with a large Canadian financial institution at fixed interest rate of 1.6%. The GIC is redeemable without penalty after 30 days.
[2]	The Company has a letter of credit with a large Canadian financial institution for $100,000. A one-year GIC for $100,000 is held on collateral. The letter of credit has a one-year expiry from the date of issue and an automatic annual extension with 30 days' notice. The letter of credit is required as a covenant to the building lease agreement in the event of a default in lease payments.

Consolidated Statements of Net

Consolidated Statements of Net (Loss) Income and Comprehensive (Loss) Income - CAD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Profit or loss [abstract]
Gross revenue	$ 48,390,103	$ 20,697,764
Excise duty	(2,744,960)
Net revenue	45,645,143	20,697,764
Cost of goods sold	19,690,162	7,680,234
Gross profit, before changes in fair value of biological assets	25,954,981	13,017,530
Fair value changes in biological assets included in inventory sold	17,301,866	8,929,308
Unrealized gain on changes in fair value of biological assets	(27,840,156)	(19,891,851)
Gross profit	36,493,271	23,980,073
Expenses
Amortization	2,169,281	964,396
General and administrative	9,014,467	3,636,808
Marketing and promotion	7,274,454	198,858
Salaries and benefits	9,823,942	3,853,314
Selling and shipping costs	8,971,434	3,803,056
Share based compensation	8,056,451	2,310,678
Operating expenses	45,310,029	14,767,110
(Loss) income from operations	(8,816,758)	9,212,963
Mortgage interest expense	(478,169)	(260,203)
Interest income	790,123
Accretion expense	(208,842)	(233,716)
Transaction costs		(204,282)
Other (loss) income	(2,033,700)	143,060
(Loss) on equity accounted investment	(385,110)	(147,056)
Impairment loss on assets	(988,160)
Loss on revaluation of derivative liability		(1,625,336)
(Loss) income before income taxes	(12,120,616)	6,885,430
Deferred income tax expense	1,433,000	0
Net (loss) income and comprehensive (loss) income	$ (13,553,616)	$ 6,885,430
Weighted average number of common shares - basic (in shares)	99,282,045	76,876,971
Weighted average number of common shares - diluted (in shares)	99,282,045	80,526,105
Earnings (loss) per share - basic (in dollars per share)	$ (0.14)	$ 0.09
Earnings (loss) per share - diluted (in dollars per share)	$ (0.14)	$ 0.09

Consolidated Statements of Chan

Consolidated Statements of Changes in Shareholders' Equity - CAD ($)		Share Capital		Share-based payment reserve	Warrants reserve	Deficit	Total
Balance at Dec. 31, 2016		$ 53,916,169			$ 3,027,398	$ (46,475,318)	$ 10,468,249
Balance (in shares) at Dec. 31, 2016		67,995,919
February 2017 Private Placement		$ 1,020,000	[1]		25,168,200		26,188,200
February 2017 Private Placement (in shares)	[1]	510,000
February 2017 Warrants issued as partial consideration for Private Placement					499,169		499,169
Warrant issuance costs					(2,068,245)		(2,068,245)
March 2017 Share issuance on exercise of convertible debt		$ 877,497	[2]				877,497
March 2017 Share issuance on exercise of convertible debt (in shares)	[2]	644,264
March 2017 Exercise of warrants		$ 1,845,919	[3]		(545,919)		1,300,000
March 2017 Exercise of warrants (in shares)	[3]	1,000,000
March 2017 Share issuance on exercise of convertible debt due on demand		$ 1,068,161	[4]				1,068,161
March 2017 Share issuance on exercise of convertible debt due on demand (in shares)	[4]	1,068,161
March 2017 Share issuance as partial consideration for Warrant Financing		$ 150,000	[5]				150,000
March 2017 Share issuance as partial consideration for Warrant Financing (in shares)	[5]	75,000
April 2017 Share issuance in lieu of services		$ 200,000	[6]				200,000
April 2017 Share issuance in lieu of services (in shares)	[6]	100,000
August 2017 Share issuance on automatic conversion of convertible debt		$ 4,062,606	[7]				4,062,606
August 2017 Share issuance on automatic conversion of convertible debt (in shares)	[7]	2,885,354
August 2017 Share issuance on automatic conversion of Special Warrants		$ 23,099,955	[8]		(23,099,955)
August 2017 Share issuance on automatic conversion of Special Warrants (in shares)	[8]	12,584,100
Exercise of warrants		$ 9,716	[9]		(4,257)		5,459
Exercise of warrants (in shares)	[9]	4,963
Exercise of stock options		$ 88,376	[10]	$ (38,376)			50,000
Exercise of stock options (in shares)	[10]	25,000
November 30, 2017 Private Placement		$ 18,447,465	[11]				18,447,465
November 30, 2017 Private Placement (in shares)	[11]	4,000,000
November 2017 Warrants issued as partial consideration for Private Placement					396,741		396,741
Exercise of broker warrants		$ 38,351	[12]		(11,343)		27,008
Exercise of broker warrants (in shares)	[12]	13,504
Share-based compensation				2,310,678			2,310,678
Net (loss) income and comprehensive (loss) income						6,885,430	6,885,430
Balance at Dec. 31, 2017		$ 104,824,215		2,272,302	3,361,789	(39,589,888)	70,868,418
Balance (in shares) at Dec. 31, 2017		90,906,265
Exercise of warrants		$ 2,206,754	[13]		(966,879)		1,239,875
Exercise of warrants (in shares)	[13]	1,127,159
Exercise of stock options		$ 3,445,256	[14]	(1,614,565)			1,830,691
Exercise of stock options (in shares)	[14]	798,101
Exercise of broker warrants		$ 2,862,769	[15]		(749,158)		2,113,611
Exercise of broker warrants (in shares)	[15]	719,556
Units issued in bought deal		$ 93,722,429	[16]		9,747,935		103,470,364
Units issued in bought deal (in shares)	[16]	12,057,405
Share-based compensation				8,056,451			8,056,451
Net (loss) income and comprehensive (loss) income						(13,553,616)	(13,553,616)
Balance at Dec. 31, 2018		$ 207,061,423		$ 8,714,188	$ 11,393,687	$ (53,143,504)	$ 174,025,794
Balance (in shares) at Dec. 31, 2018		105,608,486
[1]	On February 17, 2017, the Company issued, on a private placement basis, 510,000 common shares of the Company at a price of $2.00 per share for gross proceeds of $1,020,000. No broker fees were paid in respect of the 510,000 common shares issued.
[2]	On March 6, 2017, $600,000 of convertible debt with a total carrying value of $768,807 and $108,690 in accrued interest were converted into common shares at $1.10 per share resulting in the issuance of 644,264 common shares.
[3]	On March 9, 2017, 2 warrants were exercised to purchase 1,000,000 common shares at $1.30 per share for gross proceeds of $1,300,000. The carrying value of the warrants were $545,919.
[4]	On March 15, 2017, $1,000,000 of due on demand convertible debt and $68,161 in accrued interest were converted into common shares at $1.00 per share resulting in the issuance of 1,068,161 common shares.
[5]	As consideration for the special warrant subscription, the Company issued 75,000 common shares to the Agent on March 16, 2017. The value of the shares was measured by reference to the fair value of the common shares of the Company at the grant date. The fair value at the grant date was $2.00 per share.
[6]	On April 28, 2017, 100,000 common shares were issued as consideration for management fees to related parties. The shares were valued at $2.00 per share, as determined by the value of the services received and invoices.
[7]	On August 17, 2017, $3,040,919 of convertible debt and related derivative liability with a total carrying value of $3,929,639 and $132,967 in accrued interest were converted into common shares, in connection with the Company listing on the Canadian Securities Exchange, at $1.10 per share resulting in the issuance of 2,885,354 common shares.
[8]	On August 17, 2017, 12,584,100 Special Warrants were automatically converted into 12,584,100 common shares at $2 per share at a carrying value of $23,099,955, in connection with the Company listing on the Canadian Securities Exchange. There were no proceeds from the conversion of Special Warrants to common shares.
[9]	On September 19, 2017, 4,963 warrants were exercised to purchase 4,963 common shares at $1.10 per share for gross proceeds $5,459. The carrying value of the warrants was $4,257.
[10]	On November 27, 2017, 25,000 stock options were exercised at $2.00 per share for gross proceeds of $50,000.
[11]	On November 30, 2017, the Company issued, on a private placement basis, 4,000,000 common shares at $5.00 per share for the gross proceeds of $20,000,000. The Company's Agent for the private placement was paid an Agent's Fee of $1,100,000 and was issued Broker Warrants equaling 5.5% of the number of common shares issued as part of the private placement. Total transaction costs for the private placement were $1,552,535.
[12]	During the year ended December 31, 2017, 13,504 warrants were exercised to purchase 13,504 common shares at $2.00 per share for gross proceeds $27,008. The carrying value of the warrants was $11,343.
[13]	During the twelve months ended December 31, 2018, 1,127,159 warrants were exercised to purchase 1,127,159 common shares at $1.10 per share for gross proceeds of $1,239,875. The carrying value of the warrants was $966,879.
[14]	During the twelve months ended December 31, 2018, 798,101 were exercised at an average strike price of $2.29 per share for gross proceeds of $1,830,690. The carrying value of the options was $1,614,565.
[15]	During the twelve months ended December 31, 2018, 567,406 broker warrants were exercised to purchase 567,406 common shares at $2.00 per share for gross proceeds of $1,134,812. The carrying value of the warrants was $476,508. During the twelve months ended December 31, 2018, 121,000 broker warrants were exercised to purchase 121,000 common shares at $5.00 broker warrants per share for gross proceeds of $605,000. The carrying value of the warrants was $218,207. During the twelve months ended December 31, 2018, 31,150 broker warrants were exercised to purchase 31,150 common shares at $12.00 per share for gross proceeds of $373,800. The carrying value of the warrants was $54,442.
[16]	On June 5, 2018 the Company issued, on a bought deal basis, 11,155,000 units at $9.00 per unit for gross proceeds of $100,395,000. There were transaction costs for the bought deal of $6,156,239. Each unit issued consisted of one common share and one-half of one common share purchase warrant (see Note 15(v)). The total net proceeds of the bought deal were allocated to Common Share Capital and Warrants in the amounts of $84,490,826 and $9,747,935 respectively. On October 17, 2018, the Company finalized a partnership with Kindred Partners Inc., a wholly-owned subsidiary of Breakthru Beverage Group ("Breakthru"). Breakthru purchased 902,405 common shares of the Company at $10.23 per share for gross proceeds of $9,231,600. In addition, Breakthru was issued warrants to purchase up to an additional 2,000,000 common shares (see Note 15(vi)).

Condensed Interim Consolidated

Condensed Interim Consolidated Statements of Cash Flows - CAD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Operating Activities
Net (loss) income	$ (13,553,616)	$ 6,885,430
Items not effecting cash
Amortization	4,080,759	2,217,381
Accretion expense	208,842	233,716
Biological assets fair value adjustment expensed to cost of sales	17,301,866	8,929,309
Unrealized gain on changes in fair value of biological assets	(27,840,156)	(19,891,851)
Loss on equity accounted investment	385,110	147,056
Loss on revaluation of investment	2,087,912
Loss on revaluation of derivative liability		1,625,336
Interest (income) expense, net of interest income	(311,954)	205,664
Expenses settled with inventory		70,280
Expenses settled with issuance of common shares		135,000
Deferred income taxes	1,433,000
Share-based compensation	8,056,451	2,310,678
Cash flows from used in operations before changes in working capital	(8,151,786)	2,867,999
Changes in non-cash working capital
Harmonized sales tax recoverable	1,144,600	(2,539,718)
Inventory and biological assets	(13,857,744)	(3,529,772)
Accounts receivable	(5,414,749)	(77,210)
Prepaid expenses	(393,533)	(1,967,531)
Accounts payable and accrued liabilities	6,226,461	4,744,686
Cash flows used in operating activities	(20,446,751)	(501,546)
Investing Activities
Purchase of property and equipment	(33,019,302)	(23,993,811)
Disposal of property and equipment		136,235
Acquisition of Greenhouse and related assets		(6,500,000)
Interest received	213,651	54,539
Purchase of investments and financial assets	(13,880,231)	(283,816)
Purchase of short term investments	(200,984,420)	(900,000)
Redemption of short term investments	138,162,050	700,000
Cash flows used in investing activities	(109,508,252)	(30,786,853)
Financing Activities
Proceeds from warrant private placement, net of issue costs		43,613,330
Proceeds from exercise of warrants	3,353,486	1,332,467
Proceeds from exercise of stock options	1,830,691	50,000
Proceeds from mortgage, net of costs	13,279,638
Proceeds from share issuance, net of costs	103,470,364
Repayment of mortgage	(239,994)
Repayment of promissory note	(200,000)
Interest paid	(478,169)	(566,500)
Restricted cash held as collateral on credit card financing	765	(75,000)
Cash flows provided by financing activities	121,016,781	44,354,297
Net (decrease) increase in cash	(8,938,222)	13,065,898
Cash, at beginning of period	17,961,043	4,895,145
Cash, at end of period	$ 9,022,821	$ 17,961,043

NATURE OF OPERATIONS

NATURE OF OPERATIONS	12 Months Ended
	Dec. 31, 2018
Description Of Business Description [Abstract]
NATURE OF OPERATIONS	1. NATURE OF OPERATIONS Nature of Operations CannTrust Holdings Inc. (“CannTrust” or the “Company”) is a company incorporated under the Business Corporations Act The Company is a licensed producer and distributor of medical and recreational cannabis in Canada pursuant to the federal Cannabis Act On January 13, 2017, the Company, through its wholly owned subsidiary Elmcliffe Investments Inc. acquired various greenhouse and related assets located in the regional municipality of Niagara, Ontario. The Company received its Health Canada Sales License for its Niagara Facility in February 2018.

BASIS OF PRESENTATION

BASIS OF PRESENTATION	12 Months Ended
	Dec. 31, 2018
Disclosure Of Basis Of Presentation [Abstract]
BASIS OF PRESENTATION	2. BASIS OF PRESENTATION Basis of Preparation The consolidated financial statements have been prepared on the going concern basis, under the historical cost convention, except for biological assets and certain financial assets and liabilities which are presented at fair value, as detailed in the Company’s accounting policies. Statement of Compliance These consolidated financial statements have been prepared in compliance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”) and the interpretations of the IFRS Interpretations Committee (“IFRIC”). These consolidated financial statements were approved by the Board of Directors and authorized for issue by the Board of Directors on March 27, 2019. Basis of Consolidation These consolidated financial statements include the accounts of the Company and its controlled subsidiaries. All intercompany transactions and balances have been eliminated. 0 Entity Jurisdiction Relationship Ownership % Accounting CannTrust Inc. Ontario Wholly Owned Subsidiared 100 % Consolidated Elmcliffe Investments Inc. Ontario Wholly Owned Subsidiared 100 % Consolidated Elmcliffe Investments [No. 2] Inc. Ontario Wholly Owned Subsidiared 100 % Consolidated Greytrust Inc. Ontario Joint Venture 50 % Equity Investment Cannabis Coffee and Tea Pod Company Ltd. Ontario Joint Venture 50 % Equity Investment O Cannabis We Stand On Guard for Thee Corporation Canada Joint Venture 50 % Equity Investment Cannatrek Ltd. Australia Investment 20 % Equity Investment Stenocare A/S Denmark Investment 19 % Equity Investment Grey Wolf Animal Health Ontario Investment 6 % Equity Investment Functional Currency Translation All figures presented in these consolidated financial statements and notes thereto are reflected in Canadian dollars, which is the functional currency of the Company and its subsidiaries. Foreign currency transactions are translated using the exchange rates prevailing at the dates of the transactions. Monetary assets and liabilities denominated in foreign currencies are translated to Canadian dollars at the foreign exchange rate applicable at the statement of financial position date. Realized and unrealized exchange gains and losses are recognized through profit or loss. Non-monetary assets and liabilities that are measured in terms of historical costs in a foreign currency are translated used the exchange rate at the date of the transaction.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2018
Disclosure Of Significant Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES a. Cash Cash includes cash on deposit at banking institutions and cash held in trust. b. Short-term investments Short-term investments are comprised of GIC’s with terms to maturity of between three and twelve months or can be redeemed without penalty within 12 months from issuance. c. Property and equipment Property and equipment are measured at historical cost, which is the purchase price as well as any costs directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management, less accumulated amortization and impairment losses if applicable. Amortization is provided using the following methods and terms: Greenhouse and improvements Straight-line 20 years Buildings Straight-line 20 years Leasehold improvements Straight-line 5-10 years Production Equipment Straight-line 5 years Furniture and fixtures Straight-line 5 years Vehicles Straight-line 5 years Computer equipment Straight-line 3 years Computer software Straight-line 1 year Property and equipment's estimated residual value, useful life and amortization method are reviewed at the end of each reporting period and adjusted if necessary. When parts of an item of property and equipment have different useful lives, they are accounted for as separate components of property and equipment. Gains or losses on the disposal of an item of property and equipment are determined by comparing the proceeds from the disposal with the carrying amount of the asset and are recognized in profit or loss. d. Impairment of Property and Equipment Property and equipment are reviewed for impairment at the end of each reporting period and tested for impairment whenever events or changes in circumstances indicate that their carrying amount may not be recoverable. An impairment loss is recognized for the amount by which the asset's carrying amount exceeds its recoverable amount. The recoverable amount of property and equipment is the greater of fair value less costs to sell and value in use. In assessing value in use, estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. Impairment losses are recognized through profit or loss. Impairment losses may be reversed in a subsequent period where the impairment no longer exists or has decreased. The carrying amount after a reversal must not exceed the carrying amount (net of amortization) that would have been determined had no impairment loss been recognized. A reversal of impairment loss is recognized through profit and loss. e. Intangible Assets Intangible assets consist of exclusive rights to proprietary genetics. Intangible assets are recorded at cost less accumulated amortization. Rights are amortized on a straight-line basis in accordance with the substance of the agreements. Amortization methods, useful lives and residual values are assessed at least annually. If the Company identifies events or changes in circumstances which may indicate that their carrying amount is less than the recoverable amount, the intangible assets would be reviewed for impairment as described in note 3(d). f. Investment in Joint Venture A joint venture is a joint arrangement whereby the parties that have joint control of the arrangement have rights to the net assets of the arrangement. Investments in a joint venture are accounted for using the equity method and are initially recognized at cost. The entire carrying amount of the investment is tested for impairment annually. Under the equity method, the investment is initially recognized at cost and adjusted thereafter for the post-acquisition change in the investor’s share of comprehensive income less distributions of the joint venture. The Company’s share of its joint venture’s post-acquisition profits or losses is recognized in the statement of net income, and its share of post-acquisition movements in other comprehensive income is recognized in other comprehensive income. The cumulative post-acquisition movements are adjusted against the carrying amount of the investment. Distributions received from an investee reduce the carrying amount of the investment. If the Company’s share of losses of a joint venture equals or exceeds its interest in the joint venture, the Company does not provide for additional losses, unless it has incurred obligations or made payments on behalf of the joint venture. g. Business Combinations Judgment is used in determining whether an acquisition is a business combination or an asset acquisition. In a business combination, all identifiable assets, liabilities and contingent liabilities acquired are recorded at their fair values. One of the most significant estimates relates to the determination of the fair value of these assets and liabilities. The contingent consideration is measured at its acquisition date fair value and included as part of the consideration transferred in a business combination. Contingent consideration that is classified as equity is not re-measured at subsequent reporting dates and its subsequent settlement is accounted for within equity. Contingent consideration that is classified as an asset or a liability is re-measured at subsequent reporting dates in accordance with IFRS 9, or IAS 37 Provisions, Contingent Liabilities and Contingent Assets, as appropriate, with the corresponding gain or loss being recognized in profit or loss. For any intangible asset identified, depending on the type of intangible asset and the complexity of determining its fair value, an independent valuation expert or management may develop the fair value, using appropriate valuation techniques, which are generally based on a forecast of the total expected future net cash flows. The evaluations are linked closely to the assumptions made by management regarding the future performance of the assets concerned and any changes in the discount rate applied. Certain fair values may be estimated at the acquisition date pending confirmation or completion of the valuation process. When provisional values are used in accounting for a business combination, they may be adjusted retrospectively in subsequent periods. However, the measurement period may not exceed one year from the acquisition date. h. Leases Leases are classified as an operating lease whenever the terms of the lease do not transfer substantially all of the risks and rewards of ownership to the lessee. Lease payments are recognized as an expense on a straight-line basis over the lease term, except where another systematic basis is more representative of the time pattern in which the economic benefits are consumed. i. Revenue Recognition Revenue is recognized when control of the goods has transferred to the purchaser and the collectability is reasonably assured. This is generally when goods have been delivered, which is also when the performance obligations have been fulfilled under the terms of the related sales contract. Revenues are recorded net of discounts and incentives but inclusive of freight. Excise taxes are a production tax which become payable when a cannabis product is delivered to the customer and are not directly related to the value of revenue. j. Biological Assets The Company’s biological assets consist of cannabis plants which are not yet harvested. These biological assets are measured at fair value less costs to sell, which becomes the initial basis for the cost of finished goods inventories after harvest. Seeds are measured at fair market value. The Company capitalizes all direct and indirect costs relating to the production of biological assets during the reporting period. Unrealized gains or losses arising from changes in fair value less cost to sell during the reporting period are included in the gross margin as “Unrealized gain on changes in fair value of biological assets” in the statement of net income and comprehensive income. During the current period, the Company made a voluntary change in accounting policy to capitalize the direct and indirect costs incurred before harvest attributable to the biological asset transformation. The previous accounting policy was to expense these costs to cost of goods sold as incurred. The change in accounting policy was adopted retrospectively as reflected in the restated income statement year ended December 31, 2017. See note 5 for the impact of the voluntary change in accounting policy. The direct and indirect costs related to biological assets that are capitalized include direct costs of i) supplies/nutrients/materials, ii) salaries for personnel directly involved in growing cannabis plants, iii) utilities, iv) rent of co-generation equipment and v) depreciation of equipment directly related to production and indirect costs of i) rent and property taxes, ii) security, iii) insurance, iv) depreciation of facility and common fixed assets and v) supervision salaries. k. Inventory Inventory is valued at the lower of cost and net realizable value. Inventories of harvested cannabis are transferred from biological assets at their fair value less costs to sell at harvest, which becomes deemed cost. Any subsequent post-harvest direct and indirect costs are capitalized to inventory to the extent that cost is less than net realizable value. Net realizable value is determined as the estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale. Cost is determined using the average cost basis. Products for resale and supplies are initially recorded at cost. When the inventory is sold the capitalized costs are expensed through “Cost of goods sold” and the fair value adjustment on inventory sold is expensed through “Fair value changes in biological assets included in inventory sold”. The direct and indirect costs related to inventory that are capitalized include direct costs of i) supplies/materials, ii) salaries for personnel directly involved in production post harvest, iii) utilities, and iv) depreciation of manufacturing and packaging equipment directly related to production and indirect costs of i) rent and property taxes, ii) security, iii) insurance, iv) quality control and testing costs, v) depreciation of facility and common fixed assets and vi) supervision salaries. l. Share Capital An equity instrument is any contract that evidences a residual interest in the assets of the Company after deducting all of its liabilities. Equity instruments issued by the Company are recorded at the proceeds received, net of issue costs. For unit offerings, the Company has adopted the relative fair value method with respect to measurement of shares and warrants issued as equity units. The relative fair value method requires an allocation of the net proceeds received based on the pro rata relative fair values of the components. The fair value of the warrants is estimated using the Black-Scholes option valuation model. m. Share Issuance Costs Costs incurred in connection with the issuance of share capital are netted against the proceeds received, net of tax. Costs related to the issuance of share capital and incurred prior to issuance are recorded as deferred share issuance costs and subsequently netted against proceeds when they are received. If the share issuance is no longer expected to be completed the share issuance costs are recognized in profit or loss. n. Research and Development Research costs are expensed as incurred and are included in general and administrative expenses in the statement of net income and comprehensive income. Development expenditures are capitalized only if development costs can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable, and the Company intends to and has sufficient resources to complete development to use or sell the asset. Other development expenditures are recognized through profit and loss as incurred. o. Income Taxes Current tax expense is the expected tax payable on the taxable income for the year, using tax rates enacted or substantively enacted at year end, adjusted for amendments to tax payable with regards to previous years. Deferred tax is provided using the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for future tax consequences attributable to temporary differences between the financial statement carrying value and tax basis of assets and liabilities and the benefit of tax losses available to be carried forward for tax purposes. Deferred tax assets and liabilities are measured using enacted or substantively enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Deferred income tax assets are recorded in the consolidated financial statements if realization is considered probable. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in profit or loss in the year that the rate changes. p. Share-based Payments for Non-employees In situations where equity instruments are issued to non-employees, shares issued are recognized at the fair value of services or goods received by the entity. In situations where some or all of the goods or services received by the entity as consideration cannot be estimated reliably, they are measured at the fair value of the equity instrument granted. The fair value of the equity-settled share-based payments is recognized together with a corresponding increase in equity over a period that services are provided or goods are received. q. Share-based Compensation – Employees The Company has an employee stock option plan (“ESOP”) in place. The Company measures equity settled share-based payments based on their fair value at the grant date and recognizes compensation expense over the vesting period based on the Company’s estimate of equity instruments that will eventually vest. Fair value is measured using the Black-Scholes option pricing valuation model. Expected forfeitures are estimated at the date of grant and subsequently adjusted if further information indicates actual forfeitures may vary from the original estimate. Upon exercise stock of options, the issued shares are recorded at the corresponding amount in contributed surplus, plus the cash proceeds received. Any revisions are recognized in the consolidated statements of net (loss) income and comprehensive (loss) income such that the cumulative expense reflects the revised estimate. r. Earning/Loss per Share The Company presents basic and diluted earnings (loss) per share for its common shares. Basic earnings (loss) per share is calculated by dividing the profit or loss attributable to common shareholders by the weighted average number of common shares outstanding for the period. Diluted earnings (loss) per share is calculated by adjusting the weighted average number of common shares outstanding to assume conversion of all dilutive potential common shares. When the effect of all outstanding warrants or options are anti-dilutive during a year when the Company incurs a loss or when the exercise price exceeds market price, diluted earnings (loss) per share does not differ from basic earnings (loss) per share. s. Financial Instruments IFRS 9 was issued by the IASB on July 24, 2014 and replaced IAS 39. IFRS 9 uses a single approach to determine whether a financial instrument is measured at amortized cost, fair value through profit or loss and fair value through other comprehensive income. The Company has adopted this new standard as of its effective date on a retrospective basis without restatement. The effective date of this standard was January 1, 2018. The Company notes there was no impact on other comprehensive income or deficit from transition to IFRS 9. The new classification and measurement of the Company's financial instruments are as follows: i. Amortized Cost This category includes financial assets that are held within a business model with the objective to hold the financial assets in order to collect contractual cash flows that meet the solely principal and interest ("SPPI") criterion. Accounts receivables, accounts payables and mortgage payables are classified in this category are measured at amortized cost using the effective interest method. ii. Fair value through profit or loss (“FVTPL”) This category includes quoted equity instruments and debt instruments whose cash flow characteristics fail the SPPI criterion or are not held within a business model whose objective is either to collect contractual cash flows, or to both collect contractual cash flows and sell. Financial assets in this category are recorded at fair value with changes recognized in profit or loss. iii. Fair value through other comprehensive income (“FVOCI”) This category includes quoted equity instrument are subsequently measured at fair value with changes in fair value recognized in other comprehensive income. When an equity instrument is derecognized, the cumulative gain or loss previously recognized in OCI is not reclassified to profit and loss. Dividend income from equity instruments are not recognized in profit and loss. The Company does not have any financial assets measured at FVOCI as of December 31, 2018. IAS 39 Classification IFRS 9 Classification Cash and Cash equivalents FVTPL FVTPL Short term investments FVTPL FVTPL Marketable Securities Available for sale FVTPL Accounts receivables Amortized Cost Amortized Cost Other receivables Amortized Cost Amortized Cost Other financial assets Available for sale FVTPL Accounts payable and Accrued liabilities Amortized Cost Amortized Cost Promissory note Amortized Cost Amortized Cost Mortgage Amortized Cost Amortized Cost iv. Impairment of financial assets Under IFRS 9, the Company is required to apply an expected credit loss “ECL” model to all debt financial assets not held at FVTPL, where credit losses that are expected to transpire in futures years are provided for, irrespective of whether a loss event has occurred or not as at the balance sheet date. For trade receivables, the Company has applied the simplified approach under IFRS 9 and has calculated ECLs based on lifetime expected credit losses taking into considerations historical credit loss experience and financial factors specific to the debtors and general economic conditions. The Company has assessed the impairment of its amounts receivable using the expected credit loss model, and did not note any material differences. As a result, no incremental impairment loss has been recognized upon transition. t. Related Party Transactions Parties are considered to be related if one party has the ability, directly or indirectly, to control the other party or exercise significant influence over the other party in making financial and operating decisions. Parties are also considered to be related if they are subject to common control or common significant influence. Related parties may be individuals or corporate entities. A transaction is considered to be a related party transaction when there is a transfer of resources or obligations between related parties. Related party transactions are measured at the amounts agreed to by the parties. u. Segment Reporting A segment is a component of the Company that i) engages in business activities from which it may earn revenue and incur expenses, ii) whose operating results are reviewed by the board of directors and iii) for which discrete financial information is available. Throughout the years ended December 31, 2018 and December 31, 2017, the Company operated in one segment, the production and sale of wholesale and medicinal cannabis in Canada. v. New Standards Adopted in Current Year · Amendment to IFRS 2 ‘Share-based Payment’ was issued by the IASB in June 2016. These amendments provide clarification on how to account for certain types of share-based transaction. The amendment became effective for the Company on January 1, 2018 and did not have an impact on its consolidated financial statements. · IFRS 9 ‘Financial Instruments: Classification and Measurement’, introduces new requirements for the classification and measurement of financial instruments, a single forward-looking expected loss impairment model and a substantially reformed approach to hedge accounting. IFRS 9 is effective for annual periods beginning on or after January 1, 2018. · IFRS 15 ‘Revenue from Contracts with Customers’ was issued by the IASB in June 2014. The objective of IFRS 15 is to provide a single, comprehensive revenue recognition model for all contracts with customers. The underlying principle is that an entity will recognize revenue to depict the transfer of goods or services to customers at an amount that the entity expects to be entitled to in exchange for those goods or services. IFRS 15 became effective for the Company on January 1, 2018 and did not have a material impact on its consolidated financial statements. w. New Accounting Standards to be Adopted in the Future At the date of authorization of these consolidated financial statements, the IASB and IFRIC has issued the following new and revised Standards and Interpretations which are not yet effective for the relevant reporting periods and which the Company has not early adopted. · IFRS 16 ‘Leases’ was issued by the IASB in January 2016 and specifies the requirements to recognize, measure, present and disclose leases. IFRS 16 is effective for annual periods beginning on or after January 1, 2019. The Company intends to adopt IFRS 16 for the annual beginning on January 1, 2019 using a modified retrospective approach with the cumulative effect of adopting IFRS 16 recognized as an adjustment to opening retained earnings as at January 1, 2019. Comparative information will not be restated. The Company has completed an assessment of the impact on its consolidated financial statements. Based on this assessment, the Company expects to recognize right of use assets and lease liabilities for its operating leases of property and equipment of approximately $1.5 million to $2 million. The Company is currently committed to a future lease of $61,975,680 · IFRIC 23 ‘Uncertainty over Income Tax Treatments’ was issued by the IASB in June 2017 and specifies the interpretation to be applied to the determination of taxable profit, tax bases, unused tax losses, unused tax credits and tax rates, when there is uncertainty over income tax treatments under IAS 12. IFRIC 23 is effective for annual periods beginning on or after January 1, 2019 with early adoption permitted. The Company anticipates IFRIC 23 will have no significant impact.

SIGNIFICANT ACCOUNTING ESTIMATE

SIGNIFICANT ACCOUNTING ESTIMATES AND JUDGMENTS	12 Months Ended
	Dec. 31, 2018
Disclosure Of Accounting Judgements And Estimates [Abstract]
SIGNIFICANT ACCOUNTING ESTIMATES AND JUDGMENTS	4. SIGNIFICANT ACCOUNTING ESTIMATES AND JUDGMENTS The preparation of these consolidated financial statements in accordance with IFRS requires management to make estimates and assumptions based on management’s best knowledge of current events and actions that the Company may undertake in the future. Actual results could differ from those estimates. The impacts of such estimates are pervasive throughout the consolidated financial statements and may require accounting adjustments based on future occurrences. Revisions to accounting estimates are recognized in the period in which the estimate is revised and the revision affects both current and future periods. Significant judgments include the following: (i) Assessing whether a joint arrangement is a joint operation or a joint venture. Refer to Note 18. (ii) The valuation and recoverability of deferred taxes. The Company has determined that the realization of certain assets related to income tax losses carried forward is probable on the basis of future taxable income. Refer to Note 19. (iii) Finite-lived intangible assets are recorded at cost less accumulated amortization and accumulated impairment losses. Finite-lived intangible assets are comprised of exclusive rights to proprietary genetics. Amortization is provided on a straight-line basis. The estimated useful life and amortization method are reviewed at the end of each reporting period, with the effect of any changes in estimate being accounted for on a prospective basis. Refer to Note 10. (iv) Plants that are in pre-harvest are considered biological assets and are recorded at fair value less cost to sell at their point of harvest. Direct and indirect pre-harvest costs are capitalized to biological assets, and as they continue to grow through the pre-harvest stages, a corresponding non-cash unrealized gain on changes in fair value of biological assets is recognized. At harvest, the biological assets are transferred to inventory at their fair value less cost to sell which becomes the deemed cost of inventory. Biological assets inventory is later expensed as Cost of goods sold, including the fair value changes in biological assets included in inventory sold. Cost of goods sold includes all capitalized direct and indirect pre-harvest production costs and capitalized post-harvest direct and indirect costs relevant to inventory sold in the period. Fair value changes in biological assets prior to harvest included in inventory sold includes the non-cash gain on changes in fair value of biological assets related to inventory sold. Refer to Note 8. Significant estimates include the following: (i) Valuation of net assets acquired in acquisition. Refer to Note 6. (ii) The valuation of inventory at the lower of cost and net realizable value. Refer to Note 8. (iii) The valuation of biological assets, including estimating the stage of growth up to the point of harvest, harvesting costs, selling costs, sales price, wastage and expected yields per plant. Refer to Note 8. (iv) The estimated useful lives and residual values of Property and Equipment and related amortization included in profit and loss, as well as impairment on property and equipment. Refer to Note 9. (v) Inputs used in option valuation models used for valuation of warrants and options. Refer to Note 14 and 15. (vi) Inputs used in valuation model used for valuation of the financial assets. Refer to Note 11.

CHANGE IN ACCOUNTING POLICY

CHANGE IN ACCOUNTING POLICY	12 Months Ended
	Dec. 31, 2018
Disclosure of changes in accounting estimates [abstract]
CHANGE IN ACCOUNTING POLICY	5. CHANGE IN ACCOUNTING POLICY During the current period, the Company made a voluntary change in accounting policy to capitalize the direct and indirect costs incurred before harvest attributable to the biological asset transformation. See note 3 (j). The previous accounting policy was to expense these costs to cost of goods sold during the period in which they were incurred. These costs are capitalized to biological assets and transferred to inventory upon harvest. The capitalized costs attributable to pre-harvest costs are then expensed to cost of goods sold when the related inventory is sold. The Company believes the new policy is preferable as it matches the recognition of these costs as an expense in the same period in which the revenue is generated. There is no impact on the gross profit, net (loss) income and comprehensive (loss) income, basic and diluted earnings (loss) per share, the statement of financial position, the statement of changes in equity and cash flows used in operating activities as the change in cost of goods sold and amortization expensed to cost of goods sold is offset by the change in fair value changes in biological assets included in inventory sold and unrealized gain on changes in the fair value of biological assets. The impact of the change in accounting policy on each line item of the financial statements is shown in the table below: Year ended December 31, 2018 Year ended December 31, 2017 Statement of Net (loss) income and New policy Original policy Impact of New policy Original policy Impact of Cost of goods sold $ 19,690,162 $ 25,864,840 $ (6,174,678 ) $ 7,680,234 $ 9,017,787 $ (1,337,553 ) Amortization expensed to cost of sales - - - - 1,252,985 (1,252,985 ) Gross profit, before the unrealized gain on changes in fair value of biological assets 25,954,981 19,780,303 6,174,678 13,017,530 10,426,992 2,590,538 Fair value changes in biological assets included in inventory sold 17,301,866 23,432,761 (6,130,895 ) 8,929,308 11,302,969 (2,373,661 ) Unrealized gain on changes in fair value of biological assets (27,840,156 ) (40,145,729 ) 12,305,573 (19,891,851 ) (24,856,050 ) 4,964,199 Gross profit $ 36,493,271 $ 36,493,271 $ - $ 23,980,073 $ 23,980,073 $ - Year ended December 31, 2018 Year ended December 31, 2017 Statement of Cash Flows New policy Original policy Impact of New policy Original policy Impact of Operating Activities Items not affecting cash: Biological assets expensed to cost of sales $ 17,301,866 $ 23,432,761 $ (6,130,895 ) $ 8,929,308 $ 11,302,969 $ (2,373,661 ) Unrealized gain on changes in fair value of biological assets (27,840,156 ) (40,145,729 ) 12,305,573 (19,891,851 ) (24,856,050 ) 4,964,199 Changes in non-working capital Inventory and biological assets (13,857,744 ) (7,683,066 ) (6,174,678 ) (3,529,771 ) (939,233 ) (2,590,538 ) Cash flow used in operating activities $ (20,446,751 ) $ (20,446,751 ) $ - $ (501,546 ) $ (501,546 ) $ -

ACQUISITION

ACQUISITION	12 Months Ended
	Dec. 31, 2018
Acquisition-date fair value of total consideration transferred [abstract]
ACQUISITION	6. ACQUISITION On March 6, 2017, the Company, through its wholly owned subsidiary Elmcliffe Investments Inc. executed a Purchase and Sale Agreement to acquire various greenhouse assets located in the regional municipality of Niagara, Ontario. The aggregate purchase price for the greenhouse assets was $7,500,000. On execution of the Purchase and Sale Agreement, the operating business and all related intangible assets and intellectual property was assigned to a related party. Upon closing of the transaction, the existing operations ceased and the Company began a site conversion project in order to convert the facility into a Health Canada Approved Cannabis growth facility. With this purchase the Company enhanced its ability to serve the Canadian and International Medicinal Cannabis markets and the Adult Recreational market in Canada which became legal on October 17, 2018. The Company received its Health Canada Sales License for this facility on February 12, 2018. The Company has allocated the purchase price as follows: Assets Allocation Land $ 484,507 Residential Buildings 571,000 Greenhouses and Equipment 4,215,192 Plant and Equipment 2,115,301 Vehicles 114,000 Total of assets at fair value $ 7,500,000 Consideration of the acquisition is comprised of: Cash Consideration $ 6,500,000 Promissory note (a) 1,000,000 Total $ 7,500,000 a. As part of the consideration for the acquisition, a non-interest bearing promissory note was issued in the amount of $1,000,000 payable over 5 years in 5 consecutive annual payments of $200,000. The first payment of $200,000 was made in January 2018. The following table reflects a continuity of the Company’s promissory note: December 31, 2018 December 31, 2017 Carrying amount, January 1 $ 1,000,000 $ - Issuance of promissory note - 1,000,000 Repayment of promissory note (200,000 ) - Carrying amount $ 800,000 $ 1,000,000 less: Current portion of promissory note (200,000 ) (200,000 ) Non-Current portion of promissory note $ 600,000 $ 800,000 Costs incurred related to the acquisition totaled $204,282 which are included in 2017 transaction costs expense. No receivables, payables or inventory were acquired through the acquisition. There was no goodwill that arose from this acquisition.

RESTRICTED CASH AND SHORT-TERM

RESTRICTED CASH AND SHORT-TERM INVESTMENTS	12 Months Ended
	Dec. 31, 2018
Restricted Cash And Short Term Investments [Abstract]
RESTRICTED CASH AND SHORT-TERM INVESTMENTS	7. RESTRICTED CASH AND SHORT-TERM INVESTMENTS December 31, 2018 December 31, 2017 Short-term investment - GIC (i) $ 63,023,908 $ 201,538 Restricted cash - GIC held as collateral (ii) 100,000 100,765 Total restricted cash and short-term investments $ 63,123,908 $ 302,303 (i) The investment is a one-year GIC, redeemable every 30 days, held with a large Canadian financial institution at fixed interest rate of 1.6%. The GIC is redeemable without penalty after 30 days. (ii) The Company has a letter of credit with a large Canadian financial institution for $100,000. A one-year GIC for $100,000 is held on collateral. The letter of credit has a one-year expiry from the date of issue and an automatic annual extension with 30 days’ notice. The letter of credit is required as a covenant to the building lease agreement in the event of a default in lease payments.

INVENTORY AND BIOLOGICAL ASSETS

INVENTORY AND BIOLOGICAL ASSETS	12 Months Ended
	Dec. 31, 2018
Disclosure of reconciliation of changes in biological assets [abstract]
INVENTORY AND BIOLOGICAL ASSETS	8. INVENTORY AND BIOLOGICAL ASSETS The Company’s biological assets consist of seeds and cannabis plants. The Company’s biological assets are comprised of: December 31, 2018 December 31, 2017* Carrying amount, January 1 $ 9,843,690 $ 2,320,093 Seeds used (9,656 ) (979 ) Changes in fair value less costs to sell due to biological transformation 27,840,156 19,891,851 Production costs capitalized 12,305,573 4,964,199 Transferred to inventory upon harvest (39,477,184 ) (17,331,474 ) Carrying amount $ 10,502,579 $ 9,843,690 *Costs have been reallocated between production costs capitalized and changes in fair value less costs to sell due to biological transformation for the year ended December 31, 2017. December 31, 2018 December 31, 2017 Carrying amount of seeds $ 15,660 $ 25,316 Carrying amount of live plants 10,486,919 9,818,374 Carrying amount $ 10,502,579 $ 9,843,690 The valuation of biological assets is based on a market approach where the fair value at the point of harvest is estimated based on selling price less costs to sell. Biological assets are presented at their fair value less costs to sell up to the point of harvest. Because there is no actively traded commodity market for plants and dried product, the valuation of the biological assets is obtained using valuations techniques where the inputs are based upon unobservable market data and are classified as level 3 in the fair value hierarchy. There have been no transfers between levels. To determine fair value the Company: · counts the number of plants on hand at the end of the period and multiplies the number of plants by the expected yield in grams per plant and the expected selling price per gram; · deducts costs remaining to complete the harvest and selling costs from the expected selling price; and · applies a discount rate based on the number of days that the Company expects it will take to sell the yield from the biological assets. The significant assumptions used in determining the fair value of cannabis plants are: · stages of plant growth (days remaining until the point of harvest); · wastage of plants based on their various stages of growth; · expected yield by plant; · expected weighted average selling price per gram of harvested cannabis (based on estimated grams to be sold for the medical and recreational market); · percentage of costs incurred to date compared to the expected costs to be incurred in order to estimate fair value of an in-process plant; and · expected number of days to sell the yield from biological assets All of the plants are to be harvested as cannabis and were on a weighted average, based on expected yield, of 58% from harvest (the percentage of days remaining until the point of harvest) as at December 31, 2018 (December 31, 2017 – 52%). The average number of days from the point of propagation to the day of harvest is 112 days. The Company estimates the harvest yields for the plants at various stages of growth. At December 31, 2018, it is expected that the Company’s biological assets will yield, net of waste, approximately 13,926,974 grams (December 31, 2017 – 1,911,972 grams) of biological produce, with net selling prices ranging from $2.92 to $12.00 per gram. The selling price is determined based on historical net selling prices for medical sales and the wholesale price for projected recreational sales giving a weighted average selling price of $4.50 per gram of harvested cannabis and $1.28 per gram of harvested cannabis trim. The cost remaining to complete the harvest and selling costs range from $0.61 to $2.46 per gram with a weighted average of $1.54 per gram. The expected number of days to sell the yield from biological assets will not result in a significantly higher or lower fair value measurement. The Company’s estimates are, by nature, subject to change. Changes in the anticipated yield will be reflected in future changes in the gain or loss on biological assets. The Company performed a sensitivity analysis on the fair value of biological assets and noted that (i) a 10% decrease in selling prices would result in a $2,071,058 (December 31, 2017 - $1,261,124) decrease in the fair value of the biological assets and (ii) a 10% decrease in yield would result in a $1,050,258 (December 31, 2017 - $574,665) decrease in the fair value of the biological assets. Other unobservable inputs are less variable and will not result in significantly higher or lower fair value measurement. Inventories on hand consist of harvested finished goods, harvested cannabis in process, extracts, accessories and packaging supplies. Inventory is valued at the lower of cost and net realizable value. As at December 31, 2018, the Company held 4,471,032 grams of dry cannabis (December 31, 2017 – 626,935) and 6,887,849 grams of extracts (December 31, 2017 – 977,186). Inventory is comprised of the following items: Dried Cannabis Extracts Other December 31, 2018 Accessories $ - $ - $ 52,458 $ 52,458 Packaging and supplies - - 443,520 443,520 Work-in-Progress 11,306,993 16,505,412 - 27,812,405 Finished Goods 4,095,610 2,985,497 - 7,081,107 Total Inventory $ 15,402,603 $ 19,490,909 $ 495,978 $ 35,389,490 Dried Cannabis Extracts Other December 31, 2017 Accessories $ - $ - $ 116,974 $ 116,974 Packaging and supplies - - 137,500 137,500 Work-in-Progress 3,355,635 3,942,789 - 7,298,424 Finished Goods 1,279,339 2,126,785 - 3,406,124 Total Inventory $ 4,634,974 $ 6,069,574 $ 254,474 $ 10,959,022

PROPERTY AND EQUIPMENT

PROPERTY AND EQUIPMENT	12 Months Ended
	Dec. 31, 2018
Disclosure of detailed information about property, plant and equipment [abstract]
PROPERTY AND EQUIPMENT	9. PROPERTY AND EQUIPMENT Land Leasehold Buildings, Equipment Other Total Balance at December 31, 2016 $ - $ 2,796,356 $ - $ 4,815,487 $ 650,109 $ 8,261,952 Additions 484,507 170,568 16,528,144 13,965,236 345,356 31,493,811 Disposals - - (90,000 ) (46,235 ) - (136,235 ) Balance at December 31, 2017 $ 484,507 $ 2,966,924 $ 16,438,144 $ 18,734,488 $ 995,465 $ 39,619,528 Accumulated Amortization Balance at December 31, 2016 $ - $ (612,441 ) $ - $ (1,968,502 ) $ (471,569 ) $ (3,052,512 ) Amortization - (290,359 ) (293,922 ) (1,833,009 ) (186,041 ) (2,603,331 ) Balance at December 31, 2017 $ - $ (902,800 ) $ (293,922 ) $ (3,801,511 ) $ (657,610 ) $ (5,655,843 ) Carrying Amounts Balance at December 31, 2016 $ - $ 2,183,915 $ - $ 2,846,985 $ 178,540 $ 5,209,440 Balance at December 31, 2017 $ 484,507 $ 2,064,124 $ 16,144,222 $ 14,932,977 $ 337,855 $ 33,963,685 Balance at December 31, 2017 $ 484,507 $ 2,966,924 $ 16,438,144 $ 18,734,488 $ 995,465 $ 39,619,528 Additions 675,333 3,360,622 25,158,539 2,501,273 1,323,535 33,019,302 Balance at December 31, 2018 $ 1,159,840 $ 6,327,546 $ 41,596,683 $ 21,235,761 $ 2,319,000 $ 72,638,830 Accumulated Amortization Balance at December 31, 2017 $ - $ (902,800 ) $ (293,922 ) $ (3,801,511 ) $ (657,610 ) $ (5,655,843 ) Amortization - (424,341 ) (1,116,348 ) (2,661,805 ) (571,588 ) (4,774,082 ) Balance at December 31, 2018 $ - $ (1,327,141 ) $ (1,410,270 ) $ (6,463,316 ) $ (1,229,198 ) $ (10,429,925 ) Carrying Amounts Balance at December 31, 2017 $ 484,507 $ 2,064,124 $ 16,144,222 $ 14,932,977 $ 337,855 $ 33,963,685 Balance at December 31, 2018 $ 1,159,840 $ 5,000,405 $ 40,186,413 $ 14,772,445 $ 1,089,802 $ 62,208,905 As at December 31, 2018, $693,323 (December 31, 2017 - $385,950) of amortization from the current period remains capitalized to ending inventory. During the twelve months ended December 31, 2018, inventory expensed to cost of goods sold included amortization of $1,948,666 (December 31, 2017 - $1,252,985).

IMPAIRMENT

IMPAIRMENT	12 Months Ended
	Dec. 31, 2018
Disclosure of impairment loss and reversal of impairment loss [abstract]
IMPAIRMENT	10. IMPAIRMENT The impairment loss was recognized in relation to the intangible assets recognized during the year ended December 31, 2018 for rights to proprietary genetics. Included in the carrying amount is the cost paid for the rights to the proprietary genetics and development costs related to the acquisition of the genetics. Management considers it no longer viable for these genetics to be used in production, and the rights cannot be transferred to another party. The Company recognized an impairment loss of $988,160 reducing the carrying value to $Nil.

FINANCIAL ASSETS

FINANCIAL ASSETS	12 Months Ended
	Dec. 31, 2018
Disclosure of financial assets [abstract]
FINANCIAL ASSETS	11. FINANCIAL ASSETS December 31, 2018 December 31, 2017 Carrying amount, January 1 $ - $ - Convertible Debenture (i) 750,000 - Received Warrants on purchase of shares (ii) 151,350 - Carrying amount $ 901,350 $ - (i) On December 20, 2018, the Company made an additional investment of $750,000 in GWAH and received unsecured interest bearing convertible debentures and 150,000 warrants exercisable to purchase 150,000 shares of GWAH at $2 per share. (ii) As part of the issue of shares (see note 18 (vi)), the Company received 6,400,000 warrants exercisable to purchase 6,400,000 shares of Cannatrek at $0.40 a share. The total considerations paid was allocated to common shares and warrants in the amounts of $5,887,050 and $151,350. The warrants were valued at $151,350 at the grant date using a Black-Scholes option pricing model with the following assumptions: (i) expected dividend yield of 0%; (ii) average expected volatility of 80%; (iii) average risk-free rate of 2.09%; (iv) share price of $0.19; (v) forfeiture rate of 0%; and (vi) expected life of 1.17. The change in fair value between the grant date and December 31, 2018 was not significant. The Company performed a sensitivity analysis on the valuation of the warrants and noted that a 5% decrease in volatility would result in a $19,119 decrease in the valuation of the warrants and a 5% decrease in share price would result in a $19,640 decrease in the valuation of the warrants.

MORTGAGE

MORTGAGE	12 Months Ended
	Dec. 31, 2018
Disclosure of detailed information about borrowings [abstract]
MORTGAGE	12. MORTGAGE The following table reflects a continuity of the Company’s mortgage payable: December 31, 2018 December 31, 2017 Carrying amount, January 1 $ - $ - Advance of mortgage financing (net of costs) 9,529,638 - Second advance of mortgage financing (net of costs) 3,750,000 Accretion expense 208,842 - Mortgage payments (239,994 ) - Carrying amount $ 13,248,486 $ - Less: current portion of mortage (3,790,610 ) - Non-current portion of mortgage $ 9,457,876 $ - On February 14, 2018, the Company secured $15,000,000 of mortgage financing on the Niagara Greenhouse Facility. On closing $10,000,000 was advanced to the Company. The first advance has a two-year term and an amortization period of twenty years bearing an annual interest rate of 6.03% with a maturity date of February 15, 2020. Costs incurred related to the mortgage totaled $470,365 On December 27, 2018 the Company secured $3,750,000 being a second advance of mortgage financing. The second advance has a one-year term and an amortization period of nineteen years and two months bearing an annual interest rate of 5.45% with a maturity date of December 27, 2019. The effective interest rate of the second portion of the mortgage is 5.6%.

SHARE CAPITAL

SHARE CAPITAL	12 Months Ended
	Dec. 31, 2018
Disclosure of classes of share capital [abstract]
SHARE CAPITAL	13. SHARE CAPITAL The authorized capital stock of the Company consists of an unlimited number of common shares and unlimited number of Class A preference shares. Share Capital Number of Amount - Balance, December 31, 2016 67,995,919 $ 53,916,169 February 2017 Private Placement (i) 510,000 1,020,000 March 2017 Share issuance on exercise of convertible debt (ii) 644,264 877,497 March 2017 Exercise of warrants (iii) 1,000,000 1,845,919 March 2017 Share issuance on exercise of convertible debt due on demand (iv) 1,068,161 1,068,161 March 2017 Share issuance as partial consideration for Warrant Financing (v) 75,000 150,000 April 2017 Share issuance in lieu of services (vi) 100,000 200,000 August 2017 Share issuance on automatic conversion of convertible debt (vii) 2,885,354 4,062,606 August 2017 Share issuance on automatic conversion of Special Warrants (viii) 12,584,100 23,099,955 September 2017 Exercise of warrants (ix) 4,963 9,716 November 27, 2017 Exercise of stock options (x) 25,000 88,376 November 30, 2017 Private Placement (xi) 4,000,000 18,447,465 Exercise of broker warrants (xii) 13,504 38,351 Balance, December 30, 2017 90,906,265 104,824,215 Balance, December 31, 2017 90,906,265 $ 104,824,215 Exercise of stock options (xiii) 798,101 3,445,256 Exercise of warrants (xiv) 1,127,159 2,206,754 Exercise of broker warrants (xv) 719,556 2,862,769 Units Issued (xvi) 12,057,405 93,722,429 Balance, December 30, 2018 105,608,486 $ 207,061,423 (i) On February 17, 2017, the Company issued, on a private placement basis, 510,000 common shares of the Company at a price of $2.00 per share for gross proceeds of $1,020,000. No broker fees were paid in respect of the 510,000 common shares issued. (ii) On March 6, 2017, $600,000 of convertible debt with a total carrying value of $768,807 and $108,690 in accrued interest were converted into common shares at $1.10 per share resulting in the issuance of 644,264 common shares. (iii) On March 9, 2017, 2 warrants were exercised to purchase 1,000,000 common shares at $1.30 per share for gross proceeds of $1,300,000. The carrying value of the warrants were $545,919. (iv) On March 15, 2017, $1,000,000 of due on demand convertible debt and $68,161 in accrued interest were converted into common shares at $1.00 per share resulting in the issuance of 1,068,161 common shares. (v) As consideration for the special warrant subscription, the Company issued 75,000 common shares to the Agent on March 16, 2017. The value of the shares was measured by reference to the fair value of the common shares of the Company at the grant date. The fair value at the grant date was $2.00 per share. (vi) On April 28, 2017, 100,000 common shares were issued as consideration for management fees to related parties. The shares were valued at $2.00 per share, as determined by the value of the services received and invoices. (vii) On August 17, 2017, $3,040,919 of convertible debt and related derivative liability with a total carrying value of $3,929,639 and $132,967 in accrued interest were converted into common shares, in connection with the Company listing on the Canadian Securities Exchange, at $1.10 per share resulting in the issuance of 2,885,354 common shares. (viii) On August 17, 2017, 12,584,100 Special Warrants were automatically converted into 12,584,100 common shares at $2 per share at a carrying value of $23,099,955, in connection with the Company listing on the Canadian Securities Exchange. There were no proceeds from the conversion of Special Warrants to common shares. (ix) On September 19, 2017, 4,963 warrants were exercised to purchase 4,963 common shares at $1.10 per share for gross proceeds of $5,459. The carrying value of the warrants was $4,257. (x) On November 27, 2017, 25,000 stock options were exercised at $2.00 per share for gross proceeds of $50,000. (xi) On November 30, 2017, the Company issued, on a private placement basis, 4,000,000 common shares at $5.00 per share for the gross proceeds of $20,000,000. The Company’s Agent for the private placement was paid an Agent’s Fee of $1,100,000 and was issued Broker Warrants equaling 5.5% of the number of common shares issued as part of the private placement. Total transaction costs for the private placement were $1,552,535. (xii) During the year ended December 31, 2017, 13,504 warrants were exercised to purchase 13,504 common shares at $2.00 per share for gross proceeds $27,008. The carrying value of the warrants was $11,343. (xiii) During the twelve months ended December 31, 2018, 798,101 stock options were exercised at a weighted average strike price of $2.29 per share for gross proceeds of $1,830,690. The carrying value of the options was $1,614,565. (xiv) During the twelve months ended December 31, 2018, 1,127,159 warrants were exercised to purchase 1,127,159 common shares at $1.10 per share for gross proceeds of $1,239,875. The carrying value of the warrants was $966,879. (xv) During the twelve months ended December 31, 2018, 567,406 broker warrants were exercised to purchase 567,406 common shares at $2.00 per share for gross proceeds of $1,134,812. The carrying value of the warrants was $476,508. 121,000 broker warrants were exercised to purchase 121,000 common shares at $5.00 broker warrants per share for gross proceeds of $605,000. The carrying value of the warrants was $218,207. 31,150 broker warrants were exercised to purchase 31,150 common shares at $12.00 per share for gross proceeds of $373,800. The carrying value of the warrants was $54,442. (xvi) On June 5, 2018 the Company issued, on a bought deal basis, 11,155,000 units at $9.00 per unit for gross proceeds of $100,395,000. There were transaction costs for the bought deal of $6,156,239. Each unit issued consisted of one common share and one-half of one common share purchase warrant (see Note 15(v)). The total net proceeds of the bought deal were allocated to Common Share Capital and Warrants in the amounts of $84,490,826 and $9,747,935 respectively. On October 17, 2018, the Company finalized a partnership with Kindred Partners Inc., a wholly-owned subsidiary of Breakthru Beverage Group (“Breakthru”). Breakthru purchased 902,405 common shares of the Company at $10.23 per share for proceeds of $9,231,603. In addition, Breakthru was issued warrants to purchase up to an additional 2,000,000 common shares. Each warrant is exercisable to acquire one Common Share at an exercise price per share equal to the 5-day volume weighted average price on the TSX immediately prior to the date the applicable warrants are exercised if the Company exceeds certain sales thresholds. The warrants are valued at $Nil as the strike price will approximate the share price when exercised. Earnings per share have been calculated using the weighted average number of shares outstanding during the year on a total outstanding and fully dilutive basis. The potential conversion of warrants, convertible debt and stock options into common shares, have a dilutive effect on earnings per share. The calculation of diluted earnings (loss) per share excludes the effects of various conversions and exercise of options and warrants that would be anti-dilutive. The weighted average number of basic and diluted shares, and their respective earnings (loss) per share amounts are presented in the table below: Year ended December 31, 2018 December 31, 2017 Numerator - basic and diluted earnings per share: Net (loss) income and comprehensive (loss) income $ (13,553,616 ) $ 6,885,430 Denominator - basic earnings per share: Weighted average number of shares - basic 99,282,045 76,876,971 Denominator - diluted earnings per share: Stock Options* - 1,218,015 Warrants* - 2,431,119 Weighted average number of shares - diluted 99,282,045 80,526,105 Earnings (loss) per share - basic $ (0.14 ) $ 0.09 Earnings (loss) per share - diluted $ (0.14 ) $ 0.09 *Stock options and warrants were excluded from the weighted average number of shares as they were anti-dilutive for the year ended December 31, 2018.

STOCK OPTION PLAN

STOCK OPTION PLAN	12 Months Ended
	Dec. 31, 2018
Disclosure of terms and conditions of share-based payment arrangement [abstract]
STOCK OPTION PLAN	14. STOCK OPTION PLAN The Company has an Employee Stock Option Plan (“ESOP”) that is administered by the Board of Directors of the Company. The Board of Directors establishes expiry dates and exercise prices (at not less than market price, determined by recent transactions) at the date of grant. Options under the Plan remain exercisable in increments of 1/3 being exercisable on each of the first, second and third anniversaries from the date of grant, except as otherwise approved by the Board of Directors. The maximum number of common shares reserved for issuance for options that may be granted under the Plan is equal to 10% of the issued and outstanding common shares. The following is a summary of the changes in the Company’s ESOP options during the period: Options issued Weighted Average December 31, 2016 - $ - Options granted 3,670,500 3.40 Options forfeited (119,500 ) 2.11 Options exercised (25,000 ) 2.00 December 31, 2017 3,526,000 $ 3.45 December 31, 2017 3,526,000 $ 3.45 Options granted 2,854,500 8.17 Options forfeited (1,467,836 ) 5.38 Options exercised (798,101 ) 2.29 December 31, 2018 4,114,563 $ 7.59 The weighted average fair value of common shares issued during the year ended December 31, 2018 was $9.28 at time of exercise of options. The following is a summary of the outstanding stock options as at December 31, 2018. Options Outstanding Options Exercisable Number Weighted Average Exercise Price Number Exercisable Exercise Price 1,270,722 8.7 $0.00 - $3.50 520,702 $0.00 - $3.50 429,841 9.2 $3.51 - $6.72 46,831 $3.51 - $6.72 634,000 9.3 $6.73 - $9.00 96,317 $6.73 - $9.00 1,780,000 9.7 $9.01 - $11.88 425,000 $9.01 - $11.88 4,114,563 9.3 $ 7.59 1,088,850 $ 6.26 For the year ended December 31, 2018, the Company recorded $8,056,451 (December 31, 2017 - $2,310,678) in share-based compensation expense related to options which are measured at fair value at the date of grant and expensed over the option’s vesting period. In determining the amount of share-based compensation for the year ended December 31, 2018, the Company used the Black-Scholes option pricing model applying the following assumptions to establish the fair value of options granted during the period: Risk-free interest rate 2.30% - 2.82% Expected life of options (years) 2.5 - 6.4 Expected annualized volatility 79% - 87% Expected dividend yield Nil Forfeiture rate 6.00% Exercise price (per share) $6.70 - $11.88 Volatility was estimated by using the historical volatility of other companies having trading and volatility history that the Company considers comparable. Comparable companies with lower volatilities have been used for options granted by the Company after it was listed publicly. The expected life in years represents the period of time that options granted are expected to be outstanding. The risk-free rate was based on the zero-coupon Canada government bonds with a remaining term equal to the expected life of the options.

RESERVE FOR WARRANTS

RESERVE FOR WARRANTS	12 Months Ended
	Dec. 31, 2018
Disclosure Of Reserves Within Warrants [Abstract]
RESERVE FOR WARRANTS	15. RESERVE FOR WARRANTS The following table reflects the continuity of warrants: Number of Number of Amount Weighted Weighted December 31, 2016 1,654,801 3,654,798 $ 3,027,398 $ 1.21 1.76 February 2017 Private Placement 12,584,100 12,584,100 23,099,955 2.00 February 2017 Warrants issued as partial consideration for Private Placement 594,390 594,390 499,169 2.00 1.13 March 2017 Exercise of warrants (2 ) (1,000,000 ) (545,919 ) 1.30 August 2017 Share issuance on automatic conversion of Special Warrants (12,584,100 ) (12,584,100 ) (23,099,955 ) 2.00 September 2017 Exercise of warrants (4,963 ) (4,963 ) (4,257 ) 1.10 2.64 November 30, 2017 Warrants issued as partial consdieration for Private Placement 220,000 220,000 396,741 5.00 1.92 Exercise of broker warrants (13,504 ) (13,504 ) (11,343 ) 2.00 1.13 December 31, 2017 2,450,722 3,450,721 $ 3,361,789 $ 1.56 2.17 December 31, 2017 2,450,722 3,450,721 $ 3,361,789 $ 1.56 2.17 Exercise of warrants (i) (1,127,159 ) (1,127,159 ) (966,879 ) 1.10 Exercise of broker warrants (ii) (567,406 ) (567,406 ) (476,508 ) 2.00 Exercise of broker warrants (iii) (121,000 ) (121,000 ) (218,207 ) 5.00 Exercise of broker warrants (iv) (31,150 ) (31,150 ) (54,443 ) 12.00 Warrants issued as partial consideration of Bought Deal (v) 5,577,500 5,577,500 9,747,935 12.00 1.43 December 31, 2018 6,181,507 7,181,506 $ 11,393,687 $ 9.60 1.38 (i) During the year ended December 31, 2018, 1,127,159 warrants were exercised to purchase 1,127,159 common shares at $1.10 per share for gross proceeds of $1,239,875. The carrying value of the warrants was $966,879. (ii) During the year ended December 31, 2018, 567,406 broker warrants were exercised to purchase 567,406 common shares at $2.00 per share for gross proceeds of $1,134,812. The carrying value of the warrants was $476,508. (iii) During the year ended December 31, 2018, 121,000 broker warrants were exercised to purchase 121,000 common shares at $5.00 per share for gross proceeds of $605,000. The carrying value of the warrants was $218,207. (iv) During the year ended December 31, 2018, 31,150 broker warrants were exercised to purchase 31,150 common shares at $12.00 per share for gross proceeds of $373,800. The carrying value of the warrants was $54,443. (v) On June 5, 2018, the Company issued, on a bought deal basis, 11,155,000 units at $9.00 per unit for gross proceeds of $100,395,000. Each unit consisted of one common share and one-half of one common share purchase warrant. Each Warrant is exercisable to acquire one Common Share at an exercise price of $12.00 per share, subject to adjustment in certain events, until June 5, 2020. In the event that the daily volume weighted average trading price of the Common Shares exceeds $18.00 for 10 consecutive trading days on the Toronto Stock Exchange ("TSX"), the Company has the right to accelerate the expiry date of the warrants upon providing not less than 15 trading days' notice of such acceleration. The warrants were valued at $9,747,935 at the grant date using a weighted average value derived from a Black-Scholes pricing model that is affected by the Company’s stock price as well as assumptions regarding a number of highly complex and subjective variables. Transaction costs and agent’s fee of $636,793 were netted against the warrants. The following assumptions were used in the valuation: a) expected dividend yield of 0%; b) average expected volatility of 68 - 89%; c) average risk-free rate of 1.26 - 1.91%; d) share price of $8.89; e) forfeiture rate of 0% and; f) expected life of 0.25 - 2 years. The weighted average fair value of common shares issued on exercise of warrants during the year ended December 31, 2018 was $9.30 at the time of exercise.

COMMITMENTS

COMMITMENTS	12 Months Ended
	Dec. 31, 2018
Commitments [Abstract]
COMMITMENTS	16. COMMITMENTS The Company’s commitments consist of the following: Leases Marketing Total 2019 $ 4,055,054 $ 2,545,461 $ 6,600,515 2020 3,436,577 - 3,436,577 2021 3,407,940 - 3,407,940 2022 3,407,940 - 3,407,940 2023 3,382,177 - 3,382,177 Beyond 46,998,224 - 46,998,224 Total $ 64,687,912 $ 2,545,461 $ 67,233,373 On March 7, 2018, the Company executed a long-term non-cancellable lease agreement with Envest Corp. to provide cogeneration derived heat and power at its 450,000 square foot Greenhouse Facility. As part of the agreement, the Company is committed to $61,975,680 in aggregated lease and maintenance payments for a 20-year term to secure the rights to the Cogen equipment. The Company is currently utilizing temporary Cogen equipment system to provide heat and power while the long-term Cogen solution is being installed. The installation, once completed, will constitute a lease under IFRS 16 and the Cogen equipment will be recorded within property and equipment, with a corresponding lease liability recognized. Embedded service costs pertaining to maintenance will be separated from the lease and expensed as incurred. Additionally, the Company has a lease commitment until November 30, 2023 for the rental of the head office and production facilities. The Company entered into service contract with Breakthru to provide development of a route-to-market platform for the Company’s products in the wholesale market. Additionally, the Company has entered into a service contract with Adobe to provide advertising cloud services for a one-year term.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	12 Months Ended
	Dec. 31, 2018
Related party transactions [abstract]
RELATED PARTY TRANSACTIONS	17. RELATED PARTY TRANSACTIONS Key Management and Director Compensation During the year ended December 31, 2018, the compensation of key management and directors of the Company totaled $2,008,468 (December 31, 2017 - $1,223,773), and consisted of salaries, bonuses, and director fees. There were 1,920,000 (December 31, 2017 – 2,427,000) stock options valued at $6,421,254 (December 31, 2017 - $6,620,570) issued to key management and directors during the year ended December 31, 2018. There were 699,999 (December 31, 2017 – 25,000) stock options valued at $1,243,136 (December 31, 2017 – $88,376) exercised by key management and directors during the year ended December 31, 2018. There were 1,180,001 (December 31, 2017 – Nil) stock options valued at $4,439,950 (December 31, 2017 – Nil) forfeited by key management and directors during the year ended December 31, 2018. Key management includes those persons having authority and responsibility for planning, directing and controlling the activities, directly or indirectly, of the Company. During the year ended December 31, 2018, the Company incurred $320,000 (December 31, 2017 - $378,674) of management fees to related parties, of which $26,667 (December 31, 2017 - $26,667) was unpaid and included in accounts payable at December 31, 2018. During the year ended December 31, 2018, the Company incurred legal fees of $839,156 (December 31, 2017 - $549,387) relating to corporate services provided by a firm at which a director of the Company is a partner. Other Related Party Transactions During the year ended December 31, 2018, the Company transacted with its associate Stenocare (see Note 18 (iv)). The Company sold cannabis extracts to Stenocare in the amount of $170,336. During the year ended December 31, 2018, the Company transacted with its joint venture O’Cannabis (see Note 18 (iii)). The Company incurred $46,443 of expenses for services provided by O’Cannabis. All intercompany eliminations have been made with regards to these transactions.

INVESTMENTS

INVESTMENTS	12 Months Ended
	Dec. 31, 2018
Investments in subsidiaries, joint ventures and associates [abstract]
INVESTMENTS	18. INVESTMENTS Investment Investment Share of Net Changes in Investment CCTP (i) $ 156,073 $ 104,027 $ (88,631 ) $ - $ 171,469 GWAH (ii) - 1,000,000 (115,186 ) - 884,814 O'Cannabis (iii) - 500,000 - - 500,000 Stenocare (iv) - 487,804 (140,623 ) - 347,181 NAC (v) - 5,000,000 - (2,087,912 ) 2,912,088 Cannatrek (vi) - 5,887,050 (40,670 ) - 5,846,380 $ 156,073 $ 12,978,881 $ (385,110 ) $ (2,087,912 ) $ 10,661,932 (i) On July 15, 2015, the Company entered into a joint venture with Club Coffee L.P. (“Club Coffee”), in which each entity holds 50% of the outstanding shares of Cannabis Coffee & Tea Pod Company Ltd (“CCTP”). The Joint Venture will have access to patents and IP developed by CannTrust and Club Coffee and will build a network of licensees who will be licensed to manufacture product using patents and Intellectual Property owned by the Joint Venture. During the twelve-month period ended December 31, 2018, CCTP had a net loss and comprehensive loss after tax of $177,262 (December 31, 2017 - $294,112) of which $88,631 (December 31, 2017 - $147,056) was the Company’s share. The Company’s interest in CCTP was recorded as an equity accounted investment of $171,469 as at December 31, 2018 (December 31, 2017 - $156,073). As a condition of permitting the Company to trade its Common Shares on the TSX, the TSX required of the Company that the two license agreements entered into by CCTP with Lighthouse Strategies LLC and Silver State Wellness LLC in respect of certain geographic areas of the United States of America (collectively, the “US License Agreements”), be assigned to an entity in which the Company does not have an economic interest therein. Accordingly, on January 22, 2018 the Company and the other party to CCTP, Club Coffee, agreed to amend the Shareholder’s Agreement in which the parties agreed to assign the US License Agreements to a related party of CCTP in which the Company has no economic interest. In exchange CCTP received the option at the Company’s sole decision and after having met certain pre-stipulated conditions, to repurchase the US License Agreements for a nominal amount. These conditions are: a) marijuana being legalized federally in the United States of America, and/or b) the TSX revising its rules such that it no longer has a prohibition against its listed companies having an interest in US assets which are involved in the marijuana business, and/or c) the Common shares of the Company are involuntarily delisted from the TSX, and/or d) control of the Company is acquired by another entity, provided that the shares of the Company will be delisted from the TSX upon the change of control. The transaction constitutes a disposal of the US License and IP whereby the Company is no longer entitled to any future economic benefits from the US Licenses and IP until such time that the option to reassign is exercised. (ii) On June 26, 2018, the Company entered into a shareholder agreement with Grey Wolf Animal Health (“GWAH”) to form the joint venture, Greytrust. Both the Company and GWAH obtained 50% ownership of Greytrust and each had the right to appoint one member of the Board of Directors of Greytrust. The cost of the investment was nominal. Greytrust will develop and distribute medical cannabis Animal Healthcare products. As part of the investment, the Company had received 4,321,800 warrants exercisable to purchase 4,321,800 common shares of GWAH at $1.10 per share. On August 14, 2018, the Company executed an agreement to purchase 769,231 common shares of GWAH at $1.30 per share for a total of $1,000,000. The investment is initially measured at fair value. Subsequently, the investment is accounted for using the equity method. The Company’s share of the net losses as at December 31, 2018 is $115,186. On December 20, 2018, the Company made an additional investment of $750,000 in GWAH and received unsecured interest bearing convertible debentures and 150,000 warrants exercisable to purchase 150,000 shares of GWAH at $2 per share. (iii) On October 5, 2018, the Company acquired a 50% interest in the joint venture, O’Cannabis, a telemedicine service provider for gross proceeds of $500,000. The Company is entitled to appoint two out of four board members of O’Cannabis. The transactions of O’Cannabis had no material impact on the Company’s consolidated financial statements as of December 31, 2018. The investment is accounted for using the equity method. (iv) On March 8, 2018, the Company obtained a 25% interest in Stenocare IVS with the right to appoint half of the Board of Directors of Stenocare. Stenocare is licensed to produce and sell cannabis products in Denmark. The cost of the investment was nominal. On April 5, 2018, Stenocare changed its incorporation status from being Stenocare IVS to Stenocare A/S (“Stenocare”). On October 15, 2018, as part of Stenocare’s initial public offering, the Company purchased 272,727 common shares of Stenocare for $487,804. Stenocare began trading on the Spotlight Stock Market under the trading symbol STENO on October 26, 2018. Post IPO, the Company’s ownership decreased from 25% to 19% of the common shares outstanding of Stenocare. The Company is entitled to nominate three out of six board members of Stenocare. During the year ended December 31, 2018, Stenocare had a net loss and comprehensive loss after tax of $740,120 of which $140,623 was the Company’s share. The investment is accounted for using the equity method. (v) On October 26, 2018, the Company invested $5 million in National Access Cannabis Corp (“NAC”), a Canadian cannabis retailer. NAC’s common shares are listed on the TSX Venture Exchange under the trading symbol META. The Company also committed an additional investment of $10 million, contingent on NAC achieving specific performance targets. The Company owns approximately 3% of the outstanding common shares of NAC. The investment is initially measured at fair value. Subsequently, the investment is measured at the fair value through profit and loss. (vi) On October 26, 2018, the Company entered into a strategic partnership with an Australian licensed producer, Cannatrek Ltd (“Cannatrek”). As part of the partnership, the Company made an investment of $6,038,400 for a 6,400,000 shares or 19.8% stake in Cannatrek, with an option to maintain this percentage through any future share issuances up to and including Cannatrek completing an initial public offering. In addition, the Company had received 6,400,000 options at an exercise price of $0.40. The total considerations paid was allocated to common shares and warrants in the amounts of $5,887,050 and $151,350. The Company is entitled to appoint one out of five board members of Cannatrek. The investment is initially measured at fair value. Subsequently, the investment is accounted for using the equity method. The Company’s share of net losses is $40,670 as at December 31, 2018.

INCOME TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2018
Major components of tax expense (income) [abstract]
INCOME TAXES	19. INCOME TAXES The components of income tax provision include: 2018 2017 Current - - Deferred 1,433,000 - Income tax provision 1,433,000 - The reconciliation of the combined Canadian federal and provincial statutory income tax rate of 26.5% (2017 – 26.5%) to the effect effective tax rate is as follows: 2018 2017 (Loss) income before income taxes (12,120,616 ) 6,885,430 Combined statutory tax rate 26.5 % 26.5 % Theoretical tax recovery (3,211,963 ) 1,824,639 Non-deductible expense: Stock based compensation 2,134,960 612,330 Loss on equity accounted investments 102,054 38,970 Meals and entertainment 22,960 - Changes in unrecognized deferred tax assets 808,625 (3,238,475 ) Prior year adjustment 1,408,490 889,157 Other 167,874 (126,621 ) Income tax expense 1,433,000 - The components of deferred tax are summarized below. Deferred tax assets and liabilities have been offset where they relate to income taxes levied by the same taxation authority and the Company has the legal right and intent to offset. 2018 2017 Deferred tax assets Non-capital losses carried forward 4,702,681 4,453,360 Property, plant and equipment 1,651,542 606,812 Investments 553,015 - Share issuance costs - 120,817 Deferred tax liabilities Inventory (6,074,373 ) (5,180,989 ) Biological assets (2,265,865 ) - Net deferred tax liability (1,433,000 ) - Deferred taxes are a result of temporary differences that arise due to the differences between the income tax values and the carrying amount of assets and liabilities. Deferred tax assets have not been recognized in respect of the following deductible temporary differences because it is not probable that future taxable profit will be available against which the Company can utilize the benefits there from: 2018 2017 Non-capital losses carried forward 4,788,034 208,267 Share issuance costs 6,424,709 - 11,212,743 208,267 For income tax purposes, the Company has losses carried forward from prior years which can be used to reduce future year’s taxable income. The losses carried forward of $22,533,999, which begin to expire starting 2031.

FINANCIAL INSTRUMENTS

FINANCIAL INSTRUMENTS	12 Months Ended
	Dec. 31, 2018
Disclosure of detailed information about financial instruments [abstract]
FINANCIAL INSTRUMENTS	20. FINANCIAL INSTRUMENTS Financial Risk Management Objectives and Policies The Company manages its exposure to a number of different financial risks arising from its operations as well as its use of financial instruments including market risks (foreign currency exchange rate and interest rate), credit risk and liquidity risk through its risk management strategy. The objective of the strategy is to support the delivery of the Company's financial targets while protecting its future financial security and flexibility. Financial risks are primarily managed and monitored through operating and financing activities. The financial risks are evaluated regularly with due consideration to changes in the key economic indicators and up-to-date market information. A summary of the Company's risk exposures as it relates to financial instruments are reflected below: Interest Rate Risk Interest rate risk is the risk that the cash flows of a financial instrument will fluctuate due to changes in market interest rates. Interest rate risk on the mortgage is limited due to the fact that that it has a fixed rate. As at December 31, 2018, the Company had $63,023,908 (December 31, 2017 – $201,538) in short-term investments held with a large Canadian financial institution. The Company’s short-term investments consist of GICs which have a fixed rate of interest and can be redeemed every 30 days without penalty. The Company redeems amounts as required to fund its ongoing working capital requirements. There is minimal interest rate risk associated with the instrument. The Company has fixed rate debt, which subjects it to interest rate price risk. Liquidity Risk Liquidity risk is the risk that an entity will encounter difficulty in meeting obligations associated with financial liabilities. As at December 31, 2018, the Company had accounts payable and accrued liabilities, the current portion of promissory note and the current portion of mortgage of $16,797,068 (December 31, 2017 – $6,779,997), and cash, short-term investments, HST recoverable and accounts receivable of $79,690,443 (December 31, 2017 - $20,959,674) to meet its current obligations. The Company manages its liquidity risk by reviewing its capital requirements on an ongoing basis. In addition to the commitments disclosed in Note 16, the Company is obligated to the following contractual maturities of undiscounted cash flows: As at December 31, 2018 Total Year 1 Year 2-3 Years 4 and Accounts payable and accrued liabilities $ 12,806,458 $ 12,806,458 $ - $ - Mortgage 13,248,486 3,790,610 9,457,876 - Promissory note 800,000 200,000 400,000 200,000 Total $ 26,854,944 $ 16,797,068 $ 9,857,876 $ 200,000 Credit Risk Credit risk is the risk of an unexpected loss if a customer or third party to a financial instrument fails to meet its contractual obligations. The Company is not exposed to significant credit risk as the majority of the Company’s sales are typically paid at the time of transaction or are to government bodies. The carrying amount of cash and cash equivalents, short-term investments, restricted cash and accounts receivable represents the maximum exposure to credit risk. At December 31, 2018, this amounted to $78,298,333 (December 31, 2017 - $18,423,729). Since the inception of the Company, no losses have been suffered in relation to cash at the bank. Fair Value Disclosures Fair value represents management’s estimates of the market value at a given point in time, which may not reflect fair value in the future. These calculations are subjective in nature, involve uncertainties and are a matter of judgement and therefore cannot be determined with precision. The carrying values of the cash, short term investments, accounts receivable, accounts payable and accrued liabilities approximate their respective fair values due to the short-term nature of these instruments. The promissory note payable is non-interest bearing and its fair value approximates its carrying value. The Company uses quoted prices in active markets to determine the fair value of marketable securities. The fair value of marketable securities is based upon the level 1 hierarchy inputs. The carrying value and fair value of the mortgage is as follows: As at December 31, 2018 Carrying Value Fair Value Mortgage $ 13,248,486 $ 13,518,501 The Company uses the Government of Canada bond yield curve plus an adequate constant credit spread to discount the above financial instruments in order to determine fair value. The fair value of the mortgage payable is based upon level 2 fair value hierarchy inputs. The following table summarizes the valuation techniques and the impact of significant unobservable inputs to fair value measurement of level 3 financial instruments: Financial Asset/Liability Valuation Method Significant Impact of Cannatrek Warrants Black-Scholes option pricing Model Share price Increase/decrease in share price will result in an increase/decrease in fair value.

CAPITAL MANAGEMENT

CAPITAL MANAGEMENT	12 Months Ended
	Dec. 31, 2018
Capital Management [Abstract]
CAPITAL MANAGEMENT	21. CAPITAL MANAGEMENT The Company’s objectives when managing capital are to: · Maintain a capital structure that allows it to finance its growth strategy with cash flows from operations; · Preserve its ability to meet its financial obligations by funding the capital needs via private and public sources; and · Optimize the use of capital to provide an appropriate return on investment to its shareholders. The Company defines its capital as shareholders’ equity. The Company is not subject to externally imposed capital requirements and there has been no change with respect to the capital management strategy during the year ended December 31, 2018.

REVENUE

REVENUE	12 Months Ended
	Dec. 31, 2018
Revenue [abstract]
REVENUE	22. REVENUE The following table disaggregates revenue by major source: Canadian Medical Year ended Medical December 31, 2018 December 31, 2017 Dried Cannabis $ 11,130,996 $ 8,500,837 Extracts 22,936,664 11,291,635 Other 1,202,786 905,292 $ 35,270,446 $ 20,697,764 Wholesale Year ended December 31, 2018 December 31, 2017 Dried Cannabis $ 8,060,510 $ - Extracts 776,435 $ - Other 1,537,752 $ - $ 10,374,697 $ - Total $ 45,645,143 $ 20,697,764 Wholesale revenue includes goods and services sold to international markets, the Canadian recreational market and to third party Licensed Producers.

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2018
Disclosure Of Significant Accounting Policies [Abstract]
Cash	a. Cash Cash includes cash on deposit at banking institutions and cash held in trust.
Short-term investments	b. Short-term investments Short-term investments are comprised of GIC’s with terms to maturity of between three and twelve months or can be redeemed without penalty within 12 months from issuance.
Property and equipment	c. Property and equipment Property and equipment are measured at historical cost, which is the purchase price as well as any costs directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management, less accumulated amortization and impairment losses if applicable. Amortization is provided using the following methods and terms: Greenhouse and improvements Straight-line 20 years Buildings Straight-line 20 years Leasehold improvements Straight-line 5-10 years Production Equipment Straight-line 5 years Furniture and fixtures Straight-line 5 years Vehicles Straight-line 5 years Computer equipment Straight-line 3 years Computer software Straight-line 1 year Property and equipment's estimated residual value, useful life and amortization method are reviewed at the end of each reporting period and adjusted if necessary. When parts of an item of property and equipment have different useful lives, they are accounted for as separate components of property and equipment. Gains or losses on the disposal of an item of property and equipment are determined by comparing the proceeds from the disposal with the carrying amount of the asset and are recognized in profit or loss.
Impairment of Property and Equipment	d. Impairment of Property and Equipment Property and equipment are reviewed for impairment at the end of each reporting period and tested for impairment whenever events or changes in circumstances indicate that their carrying amount may not be recoverable. An impairment loss is recognized for the amount by which the asset's carrying amount exceeds its recoverable amount. The recoverable amount of property and equipment is the greater of fair value less costs to sell and value in use. In assessing value in use, estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. Impairment losses are recognized through profit or loss. Impairment losses may be reversed in a subsequent period where the impairment no longer exists or has decreased. The carrying amount after a reversal must not exceed the carrying amount (net of amortization) that would have been determined had no impairment loss been recognized. A reversal of impairment loss is recognized through profit and loss.
Intangible Assets	e. Intangible Assets Intangible assets consist of exclusive rights to proprietary genetics. Intangible assets are recorded at cost less accumulated amortization. Rights are amortized on a straight-line basis in accordance with the substance of the agreements. Amortization methods, useful lives and residual values are assessed at least annually. If the Company identifies events or changes in circumstances which may indicate that their carrying amount is less than the recoverable amount, the intangible assets would be reviewed for impairment as described in note 3(d).
Investment in Joint Venture	f. Investment in Joint Venture A joint venture is a joint arrangement whereby the parties that have joint control of the arrangement have rights to the net assets of the arrangement. Investments in a joint venture are accounted for using the equity method and are initially recognized at cost. The entire carrying amount of the investment is tested for impairment annually. Under the equity method, the investment is initially recognized at cost and adjusted thereafter for the post-acquisition change in the investor’s share of comprehensive income less distributions of the joint venture. The Company’s share of its joint venture’s post-acquisition profits or losses is recognized in the statement of net income, and its share of post-acquisition movements in other comprehensive income is recognized in other comprehensive income. The cumulative post-acquisition movements are adjusted against the carrying amount of the investment. Distributions received from an investee reduce the carrying amount of the investment. If the Company’s share of losses of a joint venture equals or exceeds its interest in the joint venture, the Company does not provide for additional losses, unless it has incurred obligations or made payments on behalf of the joint venture.
Business Combinations	g. Business Combinations Judgment is used in determining whether an acquisition is a business combination or an asset acquisition. In a business combination, all identifiable assets, liabilities and contingent liabilities acquired are recorded at their fair values. One of the most significant estimates relates to the determination of the fair value of these assets and liabilities. The contingent consideration is measured at its acquisition date fair value and included as part of the consideration transferred in a business combination. Contingent consideration that is classified as equity is not re-measured at subsequent reporting dates and its subsequent settlement is accounted for within equity. Contingent consideration that is classified as an asset or a liability is re-measured at subsequent reporting dates in accordance with IFRS 9, or IAS 37 Provisions, Contingent Liabilities and Contingent Assets, as appropriate, with the corresponding gain or loss being recognized in profit or loss. For any intangible asset identified, depending on the type of intangible asset and the complexity of determining its fair value, an independent valuation expert or management may develop the fair value, using appropriate valuation techniques, which are generally based on a forecast of the total expected future net cash flows. The evaluations are linked closely to the assumptions made by management regarding the future performance of the assets concerned and any changes in the discount rate applied. Certain fair values may be estimated at the acquisition date pending confirmation or completion of the valuation process. When provisional values are used in accounting for a business combination, they may be adjusted retrospectively in subsequent periods. However, the measurement period may not exceed one year from the acquisition date.
Leases	h. Leases Leases are classified as an operating lease whenever the terms of the lease do not transfer substantially all of the risks and rewards of ownership to the lessee. Lease payments are recognized as an expense on a straight-line basis over the lease term, except where another systematic basis is more representative of the time pattern in which the economic benefits are consumed.
Revenue Recognition	i. Revenue Recognition Revenue is recognized when control of the goods has transferred to the purchaser and the collectability is reasonably assured. This is generally when goods have been delivered, which is also when the performance obligations have been fulfilled under the terms of the related sales contract. Revenues are recorded net of discounts and incentives but inclusive of freight. Excise taxes are a production tax which become payable when a cannabis product is delivered to the customer and are not directly related to the value of revenue.
Biological Assets	j. Biological Assets The Company’s biological assets consist of cannabis plants which are not yet harvested. These biological assets are measured at fair value less costs to sell, which becomes the initial basis for the cost of finished goods inventories after harvest. Seeds are measured at fair market value. The Company capitalizes all direct and indirect costs relating to the production of biological assets during the reporting period. Unrealized gains or losses arising from changes in fair value less cost to sell during the reporting period are included in the gross margin as “Unrealized gain on changes in fair value of biological assets” in the statement of net income and comprehensive income. During the current period, the Company made a voluntary change in accounting policy to capitalize the direct and indirect costs incurred before harvest attributable to the biological asset transformation. The previous accounting policy was to expense these costs to cost of goods sold as incurred. The change in accounting policy was adopted retrospectively as reflected in the restated income statement year ended December 31, 2017. See note 5 for the impact of the voluntary change in accounting policy. The direct and indirect costs related to biological assets that are capitalized include direct costs of i) supplies/nutrients/materials, ii) salaries for personnel directly involved in growing cannabis plants, iii) utilities, iv) rent of co-generation equipment and v) depreciation of equipment directly related to production and indirect costs of i) rent and property taxes, ii) security, iii) insurance, iv) depreciation of facility and common fixed assets and v) supervision salaries.
Inventory	k. Inventory Inventory is valued at the lower of cost and net realizable value. Inventories of harvested cannabis are transferred from biological assets at their fair value less costs to sell at harvest, which becomes deemed cost. Any subsequent post-harvest direct and indirect costs are capitalized to inventory to the extent that cost is less than net realizable value. Net realizable value is determined as the estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale. Cost is determined using the average cost basis. Products for resale and supplies are initially recorded at cost. When the inventory is sold the capitalized costs are expensed through “Cost of goods sold” and the fair value adjustment on inventory sold is expensed through “Fair value changes in biological assets included in inventory sold”. The direct and indirect costs related to inventory that are capitalized include direct costs of i) supplies/materials, ii) salaries for personnel directly involved in production post harvest, iii) utilities, and iv) depreciation of manufacturing and packaging equipment directly related to production and indirect costs of i) rent and property taxes, ii) security, iii) insurance, iv) quality control and testing costs, v) depreciation of facility and common fixed assets and vi) supervision salaries.
Share Capital	l. Share Capital An equity instrument is any contract that evidences a residual interest in the assets of the Company after deducting all of its liabilities. Equity instruments issued by the Company are recorded at the proceeds received, net of issue costs. For unit offerings, the Company has adopted the relative fair value method with respect to measurement of shares and warrants issued as equity units. The relative fair value method requires an allocation of the net proceeds received based on the pro rata relative fair values of the components. The fair value of the warrants is estimated using the Black-Scholes option valuation model.
Share Issuance Costs	m. Share Issuance Costs Costs incurred in connection with the issuance of share capital are netted against the proceeds received, net of tax. Costs related to the issuance of share capital and incurred prior to issuance are recorded as deferred share issuance costs and subsequently netted against proceeds when they are received. If the share issuance is no longer expected to be completed the share issuance costs are recognized in profit or loss.
Research and Development	n. Research and Development Research costs are expensed as incurred and are included in general and administrative expenses in the statement of net income and comprehensive income. Development expenditures are capitalized only if development costs can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable, and the Company intends to and has sufficient resources to complete development to use or sell the asset. Other development expenditures are recognized through profit and loss as incurred.
Income Taxes	o. Income Taxes Current tax expense is the expected tax payable on the taxable income for the year, using tax rates enacted or substantively enacted at year end, adjusted for amendments to tax payable with regards to previous years. Deferred tax is provided using the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for future tax consequences attributable to temporary differences between the financial statement carrying value and tax basis of assets and liabilities and the benefit of tax losses available to be carried forward for tax purposes. Deferred tax assets and liabilities are measured using enacted or substantively enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Deferred income tax assets are recorded in the consolidated financial statements if realization is considered probable. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in profit or loss in the year that the rate changes.
Share-based Payments for Non-employees	p. Share-based Payments for Non-employees In situations where equity instruments are issued to non-employees, shares issued are recognized at the fair value of services or goods received by the entity. In situations where some or all of the goods or services received by the entity as consideration cannot be estimated reliably, they are measured at the fair value of the equity instrument granted. The fair value of the equity-settled share-based payments is recognized together with a corresponding increase in equity over a period that services are provided or goods are received.
Share-based Compensation - Employees	q. Share-based Compensation – Employees The Company has an employee stock option plan (“ESOP”) in place. The Company measures equity settled share-based payments based on their fair value at the grant date and recognizes compensation expense over the vesting period based on the Company’s estimate of equity instruments that will eventually vest. Fair value is measured using the Black-Scholes option pricing valuation model. Expected forfeitures are estimated at the date of grant and subsequently adjusted if further information indicates actual forfeitures may vary from the original estimate. Upon exercise stock of options, the issued shares are recorded at the corresponding amount in contributed surplus, plus the cash proceeds received. Any revisions are recognized in the consolidated statements of net (loss) income and comprehensive (loss) income such that the cumulative expense reflects the revised estimate.
Earning/Loss per Share	r. Earning/Loss per Share The Company presents basic and diluted earnings (loss) per share for its common shares. Basic earnings (loss) per share is calculated by dividing the profit or loss attributable to common shareholders by the weighted average number of common shares outstanding for the period. Diluted earnings (loss) per share is calculated by adjusting the weighted average number of common shares outstanding to assume conversion of all dilutive potential common shares. When the effect of all outstanding warrants or options are anti-dilutive during a year when the Company incurs a loss or when the exercise price exceeds market price, diluted earnings (loss) per share does not differ from basic earnings (loss) per share.
Financial Instruments	s. Financial Instruments IFRS 9 was issued by the IASB on July 24, 2014 and replaced IAS 39. IFRS 9 uses a single approach to determine whether a financial instrument is measured at amortized cost, fair value through profit or loss and fair value through other comprehensive income. The Company has adopted this new standard as of its effective date on a retrospective basis without restatement. The effective date of this standard was January 1, 2018. The Company notes there was no impact on other comprehensive income or deficit from transition to IFRS 9. The new classification and measurement of the Company's financial instruments are as follows: i. Amortized Cost This category includes financial assets that are held within a business model with the objective to hold the financial assets in order to collect contractual cash flows that meet the solely principal and interest ("SPPI") criterion. Accounts receivables, accounts payables and mortgage payables are classified in this category are measured at amortized cost using the effective interest method. ii. Fair value through profit or loss (“FVTPL”) This category includes quoted equity instruments and debt instruments whose cash flow characteristics fail the SPPI criterion or are not held within a business model whose objective is either to collect contractual cash flows, or to both collect contractual cash flows and sell. Financial assets in this category are recorded at fair value with changes recognized in profit or loss. iii. Fair value through other comprehensive income (“FVOCI”) This category includes quoted equity instrument are subsequently measured at fair value with changes in fair value recognized in other comprehensive income. When an equity instrument is derecognized, the cumulative gain or loss previously recognized in OCI is not reclassified to profit and loss. Dividend income from equity instruments are not recognized in profit and loss. The Company does not have any financial assets measured at FVOCI as of December 31, 2018. IAS 39 Classification IFRS 9 Classification Cash and Cash equivalents FVTPL FVTPL Short term investments FVTPL FVTPL Marketable Securities Available for sale FVTPL Accounts receivables Amortized Cost Amortized Cost Other receivables Amortized Cost Amortized Cost Other financial assets Available for sale FVTPL Accounts payable and Accrued liabilities Amortized Cost Amortized Cost Promissory note Amortized Cost Amortized Cost Mortgage Amortized Cost Amortized Cost iv. Impairment of financial assets Under IFRS 9, the Company is required to apply an expected credit loss “ECL” model to all debt financial assets not held at FVTPL, where credit losses that are expected to transpire in futures years are provided for, irrespective of whether a loss event has occurred or not as at the balance sheet date. For trade receivables, the Company has applied the simplified approach under IFRS 9 and has calculated ECLs based on lifetime expected credit losses taking into considerations historical credit loss experience and financial factors specific to the debtors and general economic conditions. The Company has assessed the impairment of its amounts receivable using the expected credit loss model, and did not note any material differences. As a result, no incremental impairment loss has been recognized upon transition.
Related Party Transactions	t. Related Party Transactions Parties are considered to be related if one party has the ability, directly or indirectly, to control the other party or exercise significant influence over the other party in making financial and operating decisions. Parties are also considered to be related if they are subject to common control or common significant influence. Related parties may be individuals or corporate entities. A transaction is considered to be a related party transaction when there is a transfer of resources or obligations between related parties. Related party transactions are measured at the amounts agreed to by the parties.
Segment Reporting	u. Segment Reporting A segment is a component of the Company that i) engages in business activities from which it may earn revenue and incur expenses, ii) whose operating results are reviewed by the board of directors and iii) for which discrete financial information is available. Throughout the years ended December 31, 2018 and December 31, 2017, the Company operated in one segment, the production and sale of wholesale and medicinal cannabis in Canada.
New Standards Adopted in Current Year	v. New Standards Adopted in Current Year · Amendment to IFRS 2 ‘Share-based Payment’ was issued by the IASB in June 2016. These amendments provide clarification on how to account for certain types of share-based transaction. The amendment became effective for the Company on January 1, 2018 and did not have an impact on its consolidated financial statements. · IFRS 9 ‘Financial Instruments: Classification and Measurement’, introduces new requirements for the classification and measurement of financial instruments, a single forward-looking expected loss impairment model and a substantially reformed approach to hedge accounting. IFRS 9 is effective for annual periods beginning on or after January 1, 2018. · IFRS 15 ‘Revenue from Contracts with Customers’ was issued by the IASB in June 2014. The objective of IFRS 15 is to provide a single, comprehensive revenue recognition model for all contracts with customers. The underlying principle is that an entity will recognize revenue to depict the transfer of goods or services to customers at an amount that the entity expects to be entitled to in exchange for those goods or services. IFRS 15 became effective for the Company on January 1, 2018 and did not have a material impact on its consolidated financial statements.
New Accounting Standards to be Adopted in the Future	w. New Accounting Standards to be Adopted in the Future At the date of authorization of these consolidated financial statements, the IASB and IFRIC has issued the following new and revised Standards and Interpretations which are not yet effective for the relevant reporting periods and which the Company has not early adopted. · IFRS 16 ‘Leases’ was issued by the IASB in January 2016 and specifies the requirements to recognize, measure, present and disclose leases. IFRS 16 is effective for annual periods beginning on or after January 1, 2019. The Company intends to adopt IFRS 16 for the annual beginning on January 1, 2019 using a modified retrospective approach with the cumulative effect of adopting IFRS 16 recognized as an adjustment to opening retained earnings as at January 1, 2019. Comparative information will not be restated. The Company has completed an assessment of the impact on its consolidated financial statements. Based on this assessment, the Company expects to recognize right of use assets and lease liabilities for its operating leases of property and equipment of approximately $1.5 million to $2 million. The Company is currently committed to a future lease of $61,975,680 · IFRIC 23 ‘Uncertainty over Income Tax Treatments’ was issued by the IASB in June 2017 and specifies the interpretation to be applied to the determination of taxable profit, tax bases, unused tax losses, unused tax credits and tax rates, when there is uncertainty over income tax treatments under IAS 12. IFRIC 23 is effective for annual periods beginning on or after January 1, 2019 with early adoption permitted. The Company anticipates IFRIC 23 will have no significant impact.

BASIS OF PRESENTATION (Tables)

BASIS OF PRESENTATION (Tables)	12 Months Ended
	Dec. 31, 2018
Disclosure Of Basis Of Presentation [Abstract]
Schedule of consolidated financial statements include the accounts of the company and its controlled subsidiaries	Entity Jurisdiction Relationship Ownership % Accounting CannTrust Inc. Ontario Wholly Owned Subsidiared 100 % Consolidated Elmcliffe Investments Inc. Ontario Wholly Owned Subsidiared 100 % Consolidated Elmcliffe Investments [No. 2] Inc. Ontario Wholly Owned Subsidiared 100 % Consolidated Greytrust Inc. Ontario Joint Venture 50 % Equity Investment Cannabis Coffee and Tea Pod Company Ltd. Ontario Joint Venture 50 % Equity Investment O Cannabis We Stand On Guard for Thee Corporation Canada Joint Venture 50 % Equity Investment Cannatrek Ltd. Australia Investment 20 % Equity Investment Stenocare A/S Denmark Investment 19 % Equity Investment Grey Wolf Animal Health Ontario Investment 6 % Equity Investment

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2018
Disclosure Of Significant Accounting Policies [Abstract]
Schedule of useful lives of property, plant and equipment	Greenhouse and improvements Straight-line 20 years Buildings Straight-line 20 years Leasehold improvements Straight-line 5-10 years Production Equipment Straight-line 5 years Furniture and fixtures Straight-line 5 years Vehicles Straight-line 5 years Computer equipment Straight-line 3 years Computer software Straight-line 1 year

CHANGE IN ACCOUNTING POLICY (Ta

CHANGE IN ACCOUNTING POLICY (Tables)	12 Months Ended
	Dec. 31, 2018
Disclosure of changes in accounting estimates [abstract]
Schedule of impact of the change in accounting policy	Year ended December 31, 2018 Year ended December 31, 2017 Statement of Net (loss) income and New policy Original policy Impact of New policy Original policy Impact of Cost of goods sold $ 19,690,162 $ 25,864,840 $ (6,174,678 ) $ 7,680,234 $ 9,017,787 $ (1,337,553 ) Amortization expensed to cost of sales - - - - 1,252,985 (1,252,985 ) Gross profit, before the unrealized gain on changes in fair value of biological assets 25,954,981 19,780,303 6,174,678 13,017,530 10,426,992 2,590,538 Fair value changes in biological assets included in inventory sold 17,301,866 23,432,761 (6,130,895 ) 8,929,308 11,302,969 (2,373,661 ) Unrealized gain on changes in fair value of biological assets (27,840,156 ) (40,145,729 ) 12,305,573 (19,891,851 ) (24,856,050 ) 4,964,199 Gross profit $ 36,493,271 $ 36,493,271 $ - $ 23,980,073 $ 23,980,073 $ - Year ended December 31, 2018 Year ended December 31, 2017 Statement of Cash Flows New policy Original policy Impact of New policy Original policy Impact of Operating Activities Items not affecting cash: Biological assets expensed to cost of sales $ 17,301,866 $ 23,432,761 $ (6,130,895 ) $ 8,929,308 $ 11,302,969 $ (2,373,661 ) Unrealized gain on changes in fair value of biological assets (27,840,156 ) (40,145,729 ) 12,305,573 (19,891,851 ) (24,856,050 ) 4,964,199 Changes in non-working capital Inventory and biological assets (13,857,744 ) (7,683,066 ) (6,174,678 ) (3,529,771 ) (939,233 ) (2,590,538 ) Cash flow used in operating activities $ (20,446,751 ) $ (20,446,751 ) $ - $ (501,546 ) $ (501,546 ) $ -

ACQUISITION (Tables)

ACQUISITION (Tables)	12 Months Ended
	Dec. 31, 2018
Acquisition-date fair value of total consideration transferred [abstract]
Schedule of allocated purchase price	Assets Allocation Land $ 484,507 Residential Buildings 571,000 Greenhouses and Equipment 4,215,192 Plant and Equipment 2,115,301 Vehicles 114,000 Total of assets at fair value $ 7,500,000
Schedule of consideration of the acquisition.	Cash Consideration $ 6,500,000 Promissory note (a) 1,000,000 Total $ 7,500,000
Schedule of continuity of the promissory note	December 31, 2018 December 31, 2017 Carrying amount, January 1 $ 1,000,000 $ - Issuance of promissory note - 1,000,000 Repayment of promissory note (200,000 ) - Carrying amount $ 800,000 $ 1,000,000 less: Current portion of promissory note (200,000 ) (200,000 ) Non-Current portion of promissory note $ 600,000 $ 800,000

RESTRICTED CASH AND SHORT-TER_2

RESTRICTED CASH AND SHORT-TERM INVESTMENTS (Tables)	12 Months Ended
	Dec. 31, 2018
Restricted Cash And Short Term Investments [Abstract]
Schedule of restricted cash and short term investments.	December 31, 2018 December 31, 2017 Short-term investment - GIC (i) $ 63,023,908 $ 201,538 Restricted cash - GIC held as collateral (ii) 100,000 100,765 Total restricted cash and short-term investments $ 63,123,908 $ 302,303 (i) The investment is a one-year GIC, redeemable every 30 days, held with a large Canadian financial institution at fixed interest rate of 1.6%. The GIC is redeemable without penalty after 30 days. (ii) The Company has a letter of credit with a large Canadian financial institution for $100,000. A one-year GIC for $100,000 is held on collateral. The letter of credit has a one-year expiry from the date of issue and an automatic annual extension with 30 days’ notice. The letter of credit is required as a covenant to the building lease agreement in the event of a default in lease payments.

INVENTORY AND BIOLOGICAL ASSE_2

INVENTORY AND BIOLOGICAL ASSETS (Tables)	12 Months Ended
	Dec. 31, 2018
Disclosure of reconciliation of changes in biological assets [abstract]
Schedule of biological assets	December 31, 2018 December 31, 2017* Carrying amount, January 1 $ 9,843,690 $ 2,320,093 Seeds used (9,656 ) (979 ) Changes in fair value less costs to sell due to biological transformation 27,840,156 19,891,851 Production costs capitalized 12,305,573 4,964,199 Transferred to inventory upon harvest (39,477,184 ) (17,331,474 ) Carrying amount $ 10,502,579 $ 9,843,690 *Costs have been reallocated between production costs capitalized and changes in fair value less costs to sell due to biological transformation for the year ended December 31, 2017.
Schedule of reallocation of cost	December 31, 2018 December 31, 2017 Carrying amount of seeds $ 15,660 $ 25,316 Carrying amount of live plants 10,486,919 9,818,374 Carrying amount $ 10,502,579 $ 9,843,690
Schedule of inventories.	Dried Cannabis Extracts Other December 31, 2018 Accessories $ - $ - $ 52,458 $ 52,458 Packaging and supplies - - 443,520 443,520 Work-in-Progress 11,306,993 16,505,412 - 27,812,405 Finished Goods 4,095,610 2,985,497 - 7,081,107 Total Inventory $ 15,402,603 $ 19,490,909 $ 495,978 $ 35,389,490 Dried Cannabis Extracts Other December 31, 2017 Accessories $ - $ - $ 116,974 $ 116,974 Packaging and supplies - - 137,500 137,500 Work-in-Progress 3,355,635 3,942,789 - 7,298,424 Finished Goods 1,279,339 2,126,785 - 3,406,124 Total Inventory $ 4,634,974 $ 6,069,574 $ 254,474 $ 10,959,022

PROPERTY AND EQUIPMENT (Tables)

PROPERTY AND EQUIPMENT (Tables)	12 Months Ended
	Dec. 31, 2018
Disclosure of detailed information about property, plant and equipment [abstract]
Schedule of property, plant and equipment	Land Leasehold Buildings, Equipment Other Total Balance at December 31, 2016 $ - $ 2,796,356 $ - $ 4,815,487 $ 650,109 $ 8,261,952 Additions 484,507 170,568 16,528,144 13,965,236 345,356 31,493,811 Disposals - - (90,000 ) (46,235 ) - (136,235 ) Balance at December 31, 2017 $ 484,507 $ 2,966,924 $ 16,438,144 $ 18,734,488 $ 995,465 $ 39,619,528 Accumulated Amortization Balance at December 31, 2016 $ - $ (612,441 ) $ - $ (1,968,502 ) $ (471,569 ) $ (3,052,512 ) Amortization - (290,359 ) (293,922 ) (1,833,009 ) (186,041 ) (2,603,331 ) Balance at December 31, 2017 $ - $ (902,800 ) $ (293,922 ) $ (3,801,511 ) $ (657,610 ) $ (5,655,843 ) Carrying Amounts Balance at December 31, 2016 $ - $ 2,183,915 $ - $ 2,846,985 $ 178,540 $ 5,209,440 Balance at December 31, 2017 $ 484,507 $ 2,064,124 $ 16,144,222 $ 14,932,977 $ 337,855 $ 33,963,685 Balance at December 31, 2017 $ 484,507 $ 2,966,924 $ 16,438,144 $ 18,734,488 $ 995,465 $ 39,619,528 Additions 675,333 3,360,622 25,158,539 2,501,273 1,323,535 33,019,302 Balance at December 31, 2018 $ 1,159,840 $ 6,327,546 $ 41,596,683 $ 21,235,761 $ 2,319,000 $ 72,638,830 Accumulated Amortization Balance at December 31, 2017 $ - $ (902,800 ) $ (293,922 ) $ (3,801,511 ) $ (657,610 ) $ (5,655,843 ) Amortization - (424,341 ) (1,116,348 ) (2,661,805 ) (571,588 ) (4,774,082 ) Balance at December 31, 2018 $ - $ (1,327,141 ) $ (1,410,270 ) $ (6,463,316 ) $ (1,229,198 ) $ (10,429,925 ) Carrying Amounts Balance at December 31, 2017 $ 484,507 $ 2,064,124 $ 16,144,222 $ 14,932,977 $ 337,855 $ 33,963,685 Balance at December 31, 2018 $ 1,159,840 $ 5,000,405 $ 40,186,413 $ 14,772,445 $ 1,089,802 $ 62,208,905

FINANCIAL ASSETS (Tables)

FINANCIAL ASSETS (Tables)	12 Months Ended
	Dec. 31, 2018
Disclosure of financial assets [abstract]
Schedule of financial assets	December 31, 2018 December 31, 2017 Carrying amount, January 1 $ - $ - Convertible Debenture (i) 750,000 - Received Warrants on purchase of shares (ii) 151,350 - Carrying amount $ 901,350 $ - (i) On December 20, 2018, the Company made an additional investment of $750,000 in GWAH and received unsecured interest bearing convertible debentures and 150,000 warrants exercisable to purchase 150,000 shares of GWAH at $2 per share. (ii) As part of the issue of shares (see note 18 (vi)), the Company received 6,400,000 warrants exercisable to purchase 6,400,000 shares of Cannatrek at $0.40 a share. The total considerations paid was allocated to common shares and warrants in the amounts of $5,887,050 and $151,350.

MORTGAGE (Tables)

MORTGAGE (Tables)	12 Months Ended
	Dec. 31, 2018
Disclosure of detailed information about borrowings [abstract]
Schedule of mortgage payable	December 31, 2018 December 31, 2017 Carrying amount, January 1 $ - $ - Advance of mortgage financing (net of costs) 9,529,638 - Second advance of mortgage financing (net of costs) 3,750,000 Accretion expense 208,842 - Mortgage payments (239,994 ) - Carrying amount $ 13,248,486 $ - Less: current portion of mortage (3,790,610 ) - Non-current portion of mortgage $ 9,457,876 $ -

SHARE CAPITAL (Tables)

SHARE CAPITAL (Tables)	12 Months Ended
	Dec. 31, 2018
Disclosure of classes of share capital [abstract]
Schedule of share capital	Share Capital Number of Amount - Balance, December 31, 2016 67,995,919 $ 53,916,169 February 2017 Private Placement (i) 510,000 1,020,000 March 2017 Share issuance on exercise of convertible debt (ii) 644,264 877,497 March 2017 Exercise of warrants (iii) 1,000,000 1,845,919 March 2017 Share issuance on exercise of convertible debt due on demand (iv) 1,068,161 1,068,161 March 2017 Share issuance as partial consideration for Warrant Financing (v) 75,000 150,000 April 2017 Share issuance in lieu of services (vi) 100,000 200,000 August 2017 Share issuance on automatic conversion of convertible debt (vii) 2,885,354 4,062,606 August 2017 Share issuance on automatic conversion of Special Warrants (viii) 12,584,100 23,099,955 September 2017 Exercise of warrants (ix) 4,963 9,716 November 27, 2017 Exercise of stock options (x) 25,000 88,376 November 30, 2017 Private Placement (xi) 4,000,000 18,447,465 Exercise of broker warrants (xii) 13,504 38,351 Balance, December 30, 2017 90,906,265 104,824,215 Balance, December 31, 2017 90,906,265 $ 104,824,215 Exercise of stock options (xiii) 798,101 3,445,256 Exercise of warrants (xiv) 1,127,159 2,206,754 Exercise of broker warrants (xv) 719,556 2,862,769 Units Issued (xvi) 12,057,405 93,722,429 Balance, December 30, 2018 105,608,486 $ 207,061,423 (i) On February 17, 2017, the Company issued, on a private placement basis, 510,000 common shares of the Company at a price of $2.00 per share for gross proceeds of $1,020,000. No broker fees were paid in respect of the 510,000 common shares issued. (ii) On March 6, 2017, $600,000 of convertible debt with a total carrying value of $768,807 and $108,690 in accrued interest were converted into common shares at $1.10 per share resulting in the issuance of 644,264 common shares. (iii) On March 9, 2017, 2 warrants were exercised to purchase 1,000,000 common shares at $1.30 per share for gross proceeds of $1,300,000. The carrying value of the warrants were $545,919. (iv) On March 15, 2017, $1,000,000 of due on demand convertible debt and $68,161 in accrued interest were converted into common shares at $1.00 per share resulting in the issuance of 1,068,161 common shares. (v) As consideration for the special warrant subscription, the Company issued 75,000 common shares to the Agent on March 16, 2017. The value of the shares was measured by reference to the fair value of the common shares of the Company at the grant date. The fair value at the grant date was $2.00 per share. (vi) On April 28, 2017, 100,000 common shares were issued as consideration for management fees to related parties. The shares were valued at $2.00 per share, as determined by the value of the services received and invoices. (vii) On August 17, 2017, $3,040,919 of convertible debt and related derivative liability with a total carrying value of $3,929,639 and $132,967 in accrued interest were converted into common shares, in connection with the Company listing on the Canadian Securities Exchange, at $1.10 per share resulting in the issuance of 2,885,354 common shares. (viii) On August 17, 2017, 12,584,100 Special Warrants were automatically converted into 12,584,100 common shares at $2 per share at a carrying value of $23,099,955, in connection with the Company listing on the Canadian Securities Exchange. There were no proceeds from the conversion of Special Warrants to common shares. (ix) On September 19, 2017, 4,963 warrants were exercised to purchase 4,963 common shares at $1.10 per share for gross proceeds of $5,459. The carrying value of the warrants was $4,257. (x) On November 27, 2017, 25,000 stock options were exercised at $2.00 per share for gross proceeds of $50,000. (xi) On November 30, 2017, the Company issued, on a private placement basis, 4,000,000 common shares at $5.00 per share for the gross proceeds of $20,000,000. The Company’s Agent for the private placement was paid an Agent’s Fee of $1,100,000 and was issued Broker Warrants equaling 5.5% of the number of common shares issued as part of the private placement. Total transaction costs for the private placement were $1,552,535. (xii) During the year ended December 31, 2017, 13,504 warrants were exercised to purchase 13,504 common shares at $2.00 per share for gross proceeds $27,008. The carrying value of the warrants was $11,343. (xiii) During the twelve months ended December 31, 2018, 798,101 stock options were exercised at a weighted average strike price of $2.29 per share for gross proceeds of $1,830,690. The carrying value of the options was $1,614,565. (xiv) During the twelve months ended December 31, 2018, 1,127,159 warrants were exercised to purchase 1,127,159 common shares at $1.10 per share for gross proceeds of $1,239,875. The carrying value of the warrants was $966,879. (xv) During the twelve months ended December 31, 2018, 567,406 broker warrants were exercised to purchase 567,406 common shares at $2.00 per share for gross proceeds of $1,134,812. The carrying value of the warrants was $476,508. 121,000 broker warrants were exercised to purchase 121,000 common shares at $5.00 broker warrants per share for gross proceeds of $605,000. The carrying value of the warrants was $218,207. 31,150 broker warrants were exercised to purchase 31,150 common shares at $12.00 per share for gross proceeds of $373,800. The carrying value of the warrants was $54,442. (xvi) On June 5, 2018 the Company issued, on a bought deal basis, 11,155,000 units at $9.00 per unit for gross proceeds of $100,395,000. There were transaction costs for the bought deal of $6,156,239. Each unit issued consisted of one common share and one-half of one common share purchase warrant (see Note 15(v)). The total net proceeds of the bought deal were allocated to Common Share Capital and Warrants in the amounts of $84,490,826 and $9,747,935 respectively. On October 17, 2018, the Company finalized a partnership with Kindred Partners Inc., a wholly-owned subsidiary of Breakthru Beverage Group (“Breakthru”). Breakthru purchased 902,405 common shares of the Company at $10.23 per share for proceeds of $9,231,603. In addition, Breakthru was issued warrants to purchase up to an additional 2,000,000 common shares.
Schedule of earnings per share	Year ended December 31, 2018 December 31, 2017 Numerator - basic and diluted earnings per share: Net (loss) income and comprehensive (loss) income $ (13,553,616 ) $ 6,885,430 Denominator - basic earnings per share: Weighted average number of shares - basic 99,282,045 76,876,971 Denominator - diluted earnings per share: Stock Options* - 1,218,015 Warrants* - 2,431,119 Weighted average number of shares - diluted 99,282,045 80,526,105 Earnings (loss) per share - basic $ (0.14 ) $ 0.09 Earnings (loss) per share - diluted $ (0.14 ) $ 0.09 *Stock options and warrants were excluded from the weighted average number of shares as they were anti-dilutive for the year ended December 31, 2018.

STOCK OPTION PLAN (Tables)

STOCK OPTION PLAN (Tables)	12 Months Ended
	Dec. 31, 2018
Disclosure of terms and conditions of share-based payment arrangement [abstract]
Schedule of change in ESOP options	Options issued Weighted Average December 31, 2016 - $ - Options granted 3,670,500 3.40 Options forfeited (119,500 ) 2.11 Options exercised (25,000 ) 2.00 December 31, 2017 3,526,000 $ 3.45 December 31, 2017 3,526,000 $ 3.45 Options granted 2,854,500 8.17 Options forfeited (1,467,836 ) 5.38 Options exercised (798,101 ) 2.29 December 31, 2018 4,114,563 $ 7.59
Schedule of outstanding stock options	Options Outstanding Options Exercisable Number Outstanding Weighted Average Exercise Price Number Exercisable Exercise Price 1,270,722 8.7 $0.00 - $3.50 520,702 $0.00 - $3.50 429,841 9.2 $3.51 - $6.72 46,831 $3.51 - $6.72 634,000 9.3 $6.73 - $9.00 96,317 $6.73 - $9.00 1,780,000 9.7 $9.01 - $11.88 425,000 $9.01 - $11.88 4,114,563 9.3 $7.59 1,088,850 $6.26
Schedule of assumptions use to fair value of options granted	Risk-free interest rate 2.30% - 2.82% Expected life of options (years) 2.5 - 6.4 Expected annualized volatility 79% - 87% Expected dividend yield Nil Forfeiture rate 6.00% Exercise price (per share) $6.70 - $11.88

RESERVE FOR WARRANTS (Tables)

RESERVE FOR WARRANTS (Tables)	12 Months Ended
	Dec. 31, 2018
Disclosure Of Reserves Within Warrants [Abstract]
Schedule of continuity of warrants	Number of Number of Amount Weighted Weighted December 31, 2016 1,654,801 3,654,798 $ 3,027,398 $ 1.21 1.76 February 2017 Private Placement 12,584,100 12,584,100 23,099,955 2.00 February 2017 Warrants issued as partial consideration for Private Placement 594,390 594,390 499,169 2.00 1.13 March 2017 Exercise of warrants (2 ) (1,000,000 ) (545,919 ) 1.30 August 2017 Share issuance on automatic conversion of Special Warrants (12,584,100 ) (12,584,100 ) (23,099,955 ) 2.00 September 2017 Exercise of warrants (4,963 ) (4,963 ) (4,257 ) 1.10 2.64 November 30, 2017 Warrants issued as partial consdieration for Private Placement 220,000 220,000 396,741 5.00 1.92 Exercise of broker warrants (13,504 ) (13,504 ) (11,343 ) 2.00 1.13 December 31, 2017 2,450,722 3,450,721 $ 3,361,789 $ 1.56 2.17 December 31, 2017 2,450,722 3,450,721 $ 3,361,789 $ 1.56 2.17 Exercise of warrants (i) (1,127,159 ) (1,127,159 ) (966,879 ) 1.10 Exercise of broker warrants (ii) (567,406 ) (567,406 ) (476,508 ) 2.00 Exercise of broker warrants (iii) (121,000 ) (121,000 ) (218,207 ) 5.00 Exercise of broker warrants (iv) (31,150 ) (31,150 ) (54,443 ) 12.00 Warrants issued as partial consideration of Bought Deal (v) 5,577,500 5,577,500 9,747,935 12.00 1.43 December 31, 2018 6,181,507 7,181,506 $ 11,393,687 $ 9.60 1.38 (i) During the year ended December 31, 2018, 1,127,159 warrants were exercised to purchase 1,127,159 common shares at $1.10 per share for gross proceeds of $1,239,875. The carrying value of the warrants was $966,879. (ii) During the year ended December 31, 2018, 567,406 broker warrants were exercised to purchase 567,406 common shares at $2.00 per share for gross proceeds of $1,134,812. The carrying value of the warrants was $476,508. (iii) During the year ended December 31, 2018, 121,000 broker warrants were exercised to purchase 121,000 common shares at $5.00 per share for gross proceeds of $605,000. The carrying value of the warrants was $218,207. (iv) During the year ended December 31, 2018, 31,150 broker warrants were exercised to purchase 31,150 common shares at $12.00 per share for gross proceeds of $373,800. The carrying value of the warrants was $54,443. (v) On June 5, 2018, the Company issued, on a bought deal basis, 11,155,000 units at $9.00 per unit for gross proceeds of $100,395,000. Each unit consisted of one common share and one-half of one common share purchase warrant. Each Warrant is exercisable to acquire one Common Share at an exercise price of $12.00 per share, subject to adjustment in certain events, until June 5, 2020. In the event that the daily volume weighted average trading price of the Common Shares exceeds $18.00 for 10 consecutive trading days on the Toronto Stock Exchange ("TSX"), the Company has the right to accelerate the expiry date of the warrants upon providing not less than 15 trading days' notice of such acceleration. The warrants were valued at $9,747,935 at the grant date using a weighted average value derived from a Black-Scholes pricing model that is affected by the Company’s stock price as well as assumptions regarding a number of highly complex and subjective variables. Transaction costs and agent’s fee of $636,793 were netted against the warrants. The following assumptions were used in the valuation: a) expected dividend yield of 0%; b) average expected volatility of 68 - 89%; c) average risk-free rate of 1.26 - 1.91%; d) share price of $8.89; e) forfeiture rate of 0% and; f) expected life of 0.25 - 2 years.

COMMITMENTS (Tables)

COMMITMENTS (Tables)	12 Months Ended
	Dec. 31, 2018
Commitments [Abstract]
Schedule of commitments	Leases Marketing Total 2019 $ 4,055,054 $ 2,545,461 $ 6,600,515 2020 3,436,577 - 3,436,577 2021 3,407,940 - 3,407,940 2022 3,407,940 - 3,407,940 2023 3,382,177 - 3,382,177 Beyond 46,998,224 - 46,998,224 Total $ 64,687,912 $ 2,545,461 $ 67,233,373

INVESTMENTS (Tables)

INVESTMENTS (Tables)	12 Months Ended
	Dec. 31, 2018
Investments in subsidiaries, joint ventures and associates [abstract]
Schedule of investments	Investment Investment Share of Net Changes in Investment CCTP (i) $ 156,073 $ 104,027 $ (88,631 ) $ - $ 171,469 GWAH (ii) - 1,000,000 (115,186 ) - 884,814 O'Cannabis (iii) - 500,000 - - 500,000 Stenocare (iv) - 487,804 (140,623 ) - 347,181 NAC (v) - 5,000,000 - (2,087,912 ) 2,912,088 Cannatrek (vi) - 5,887,050 (40,670 ) - 5,846,380 $ 156,073 $ 12,978,881 $ (385,110 ) $ (2,087,912 ) $ 10,661,932 (i) On July 15, 2015, the Company entered into a joint venture with Club Coffee L.P. (“Club Coffee”), in which each entity holds 50% of the outstanding shares of Cannabis Coffee & Tea Pod Company Ltd (“CCTP”). The Joint Venture will have access to patents and IP developed by CannTrust and Club Coffee and will build a network of licensees who will be licensed to manufacture product using patents and Intellectual Property owned by the Joint Venture. During the twelve-month period ended December 31, 2018, CCTP had a net loss and comprehensive loss after tax of $177,262 (December 31, 2017 - $294,112) of which $88,631 (December 31, 2017 - $147,056) was the Company’s share. The Company’s interest in CCTP was recorded as an equity accounted investment of $171,469 as at December 31, 2018 (December 31, 2017 - $156,073). As a condition of permitting the Company to trade its Common Shares on the TSX, the TSX required of the Company that the two license agreements entered into by CCTP with Lighthouse Strategies LLC and Silver State Wellness LLC in respect of certain geographic areas of the United States of America (collectively, the “US License Agreements”), be assigned to an entity in which the Company does not have an economic interest therein. Accordingly, on January 22, 2018 the Company and the other party to CCTP, Club Coffee, agreed to amend the Shareholder’s Agreement in which the parties agreed to assign the US License Agreements to a related party of CCTP in which the Company has no economic interest. In exchange CCTP received the option at the Company’s sole decision and after having met certain pre-stipulated conditions, to repurchase the US License Agreements for a nominal amount. These conditions are: a) marijuana being legalized federally in the United States of America, and/or b) the TSX revising its rules such that it no longer has a prohibition against its listed companies having an interest in US assets which are involved in the marijuana business, and/or c) the Common shares of the Company are involuntarily delisted from the TSX, and/or d) control of the Company is acquired by another entity, provided that the shares of the Company will be delisted from the TSX upon the change of control. The transaction constitutes a disposal of the US License and IP whereby the Company is no longer entitled to any future economic benefits from the US Licenses and IP until such time that the option to reassign is exercised. (ii) On June 26, 2018, the Company entered into a shareholder agreement with Grey Wolf Animal Health (“GWAH”) to form the joint venture, Greytrust. Both the Company and GWAH obtained 50% ownership of Greytrust and each had the right to appoint one member of the Board of Directors of Greytrust. The cost of the investment was nominal. Greytrust will develop and distribute medical cannabis Animal Healthcare products. As part of the investment, the Company had received 4,321,800 warrants exercisable to purchase 4,321,800 common shares of GWAH at $1.10 per share. On August 14, 2018, the Company executed an agreement to purchase 769,231 common shares of GWAH at $1.30 per share for a total of $1,000,000. The investment is initially measured at fair value. Subsequently, the investment is accounted for using the equity method. The Company’s share of the net losses as at December 31, 2018 is $115,186. On December 20, 2018, the Company made an additional investment of $750,000 in GWAH and received unsecured interest bearing convertible debentures and 150,000 warrants exercisable to purchase 150,000 shares of GWAH at $2 per share. (iii) On October 5, 2018, the Company acquired a 50% interest in the joint venture, O’Cannabis, a telemedicine service provider for gross proceeds of $500,000. The Company is entitled to appoint two out of four board members of O’Cannabis. The transactions of O’Cannabis had no material impact on the Company’s consolidated financial statements as of December 31, 2018. The investment is accounted for using the equity method. (iv) On March 8, 2018, the Company obtained a 25% interest in Stenocare IVS with the right to appoint half of the Board of Directors of Stenocare. Stenocare is licensed to produce and sell cannabis products in Denmark. The cost of the investment was nominal. On April 5, 2018, Stenocare changed its incorporation status from being Stenocare IVS to Stenocare A/S (“Stenocare”). On October 15, 2018, as part of Stenocare’s initial public offering, the Company purchased 272,727 common shares of Stenocare for $487,804. Stenocare began trading on the Spotlight Stock Market under the trading symbol STENO on October 26, 2018. Post IPO, the Company’s ownership decreased from 25% to 19% of the common shares outstanding of Stenocare. The Company is entitled to nominate three out of six board members of Stenocare. During the year ended December 31, 2018, Stenocare had a net loss and comprehensive loss after tax of $740,120 of which $140,623 was the Company’s share. The investment is accounted for using the equity method. (v) On October 26, 2018, the Company invested $5 million in National Access Cannabis Corp (“NAC”), a Canadian cannabis retailer. NAC’s common shares are listed on the TSX Venture Exchange under the trading symbol META. The Company also committed an additional investment of $10 million, contingent on NAC achieving specific performance targets. The Company owns approximately 3% of the outstanding common shares of NAC. The investment is initially measured at fair value. Subsequently, the investment is measured at the fair value through profit and loss. (vi) On October 26, 2018, the Company entered into a strategic partnership with an Australian licensed producer, Cannatrek Ltd (“Cannatrek”). As part of the partnership, the Company made an investment of $6,038,400 for a 6,400,000 shares or 19.8% stake in Cannatrek, with an option to maintain this percentage through any future share issuances up to and including Cannatrek completing an initial public offering. In addition, the Company had received 6,400,000 options at an exercise price of $0.40. The total considerations paid was allocated to common shares and warrants in the amounts of $5,887,050 and $151,350. The Company is entitled to appoint one out of five board members of Cannatrek. The investment is initially measured at fair value. Subsequently, the investment is accounted for using the equity method. The Company’s share of net losses is $40,670 as at December 31, 2018.

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2018
Major components of tax expense (income) [abstract]
Schedule of components of income tax provision	2018 2017 Current - - Deferred 1,433,000 - Income tax provision 1,433,000 -
Schedule of statutory income tax rate	2018 2017 (Loss) income before income taxes (12,120,616 ) 6,885,430 Combined statutory tax rate 26.5 % 26.5 % Theoretical tax recovery (3,211,963 ) 1,824,639 Non-deductible expense: Stock based compensation 2,134,960 612,330 Loss on equity accounted investments 102,054 38,970 Meals and entertainment 22,960 - Changes in unrecognized deferred tax assets 808,625 (3,238,475 ) Prior year adjustment 1,408,490 889,157 Other 167,874 (126,621 ) Income tax expense 1,433,000 -
Schedule of components of deferred tax	2018 2017 Deferred tax assets Non-capital losses carried forward 4,702,681 4,453,360 Property, plant and equipment 1,651,542 606,812 Investments 553,015 - Share issuance costs - 120,817 Deferred tax liabilities Inventory (6,074,373 ) (5,180,989 ) Biological assets (2,265,865 ) - Net deferred tax liability (1,433,000 ) -
Schedule of temporary differences	2018 2017 Non-capital losses carried forward 4,788,034 208,267 Share issuance costs 6,424,709 - 11,212,743 208,267

FINANCIAL INSTRUMENTS (Tables)

FINANCIAL INSTRUMENTS (Tables)	12 Months Ended
	Dec. 31, 2018
Disclosure of detailed information about financial instruments [abstract]
Schedule of contractual maturities	As at December 31, 2018 Total Year 1 Year 2-3 Years 4 and Accounts payable and accrued liabilities $ 12,806,458 $ 12,806,458 $ - $ - Mortgage 13,248,486 3,790,610 9,457,876 - Promissory note 800,000 200,000 400,000 200,000 Total $ 26,854,944 $ 16,797,068 $ 9,857,876 $ 200,000
Schedule of carrying value and fair value of mortgage	As at December 31, 2018 Carrying Value Fair Value Mortgage $ 13,248,486 $ 13,518,501
Schedule of significant unobservable inputs fair value measurement of level 3 financial instruments	Financial Asset/Liability Valuation Method Significant Impact of Cannatrek Warrants Black-Scholes option pricing Model Share price Increase/decrease in share price will result in an increase/decrease in fair value.

REVENUE (Tables)

REVENUE (Tables)	12 Months Ended
	Dec. 31, 2018
Revenue [abstract]
Schedule of disaggregates revenue	Canadian Medical Year ended Medical December 31, 2018 December 31, 2017 Dried Cannabis $ 11,130,996 $ 8,500,837 Extracts 22,936,664 11,291,635 Other 1,202,786 905,292 $ 35,270,446 $ 20,697,764 Wholesale Year ended December 31, 2018 December 31, 2017 Dried Cannabis $ 8,060,510 $ - Extracts 776,435 $ - Other 1,537,752 $ - $ 10,374,697 $ - Total $ 45,645,143 $ 20,697,764

NATURE OF OPERATIONS (Detail Te

NATURE OF OPERATIONS (Detail Textuals)	12 Months Ended
	Dec. 31, 2018
Cannabis Coffee and Tea Pod Company Ltd.
Description Of Nature Of Operations [Line Items]
Percentage of outstanding shares	50.00%
O'Cannabis
Description Of Nature Of Operations [Line Items]
Percentage of outstanding shares	50.00%
Greytrust Inc.
Description Of Nature Of Operations [Line Items]
Percentage of outstanding shares	50.00%

BASIS OF PRESENTATION (Details)

BASIS OF PRESENTATION (Details)	12 Months Ended
	Dec. 31, 2018
CannTrust Inc.
Disclosure of information about consolidated structured entities [line items]
Proportion of ownership interest in subsidiary	100.00%
Elmcliffe Investments Inc.
Disclosure of information about consolidated structured entities [line items]
Proportion of ownership interest in subsidiary	100.00%
Elmcliffe Investments [No. 2] Inc.
Disclosure of information about consolidated structured entities [line items]
Proportion of ownership interest in subsidiary	100.00%
Cannabis Coffee and Tea Pod Company Ltd.
Disclosure of information about consolidated structured entities [line items]
Proportion of ownership interest in joint venture and investment	50.00%
O'Cannabis
Disclosure of information about consolidated structured entities [line items]
Proportion of ownership interest in joint venture and investment	50.00%
Cannatrek Ltd.
Disclosure of information about consolidated structured entities [line items]
Proportion of ownership interest in joint venture and investment	20.00%
Stenocare A/S
Disclosure of information about consolidated structured entities [line items]
Proportion of ownership interest in joint venture and investment	19.00%
Grey Wolf Animal Health
Disclosure of information about consolidated structured entities [line items]
Proportion of ownership interest in joint venture and investment	6.00%

SUMMARY OF SIGNIFICANT ACCOUN_4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)	12 Months Ended
	Dec. 31, 2018
Greenhouse and Improvements
Disclosure of detailed information about property, plant and equipment [line items]
Amortization method	Straight-line
Useful life	20 years
Buildings
Disclosure of detailed information about property, plant and equipment [line items]
Amortization method	Straight-line
Useful life	20 years
Leasehold improvements
Disclosure of detailed information about property, plant and equipment [line items]
Amortization method	Straight-line
Useful life	5-10 years
Production Equipment
Disclosure of detailed information about property, plant and equipment [line items]
Amortization method	Straight-line
Useful life	5 years
Furniture and fixtures
Disclosure of detailed information about property, plant and equipment [line items]
Amortization method	Straight-line
Useful life	5 years
Vehicles
Disclosure of detailed information about property, plant and equipment [line items]
Amortization method	Straight-line
Useful life	5 years
Computer equipment
Disclosure of detailed information about property, plant and equipment [line items]
Amortization method	Straight-line
Useful life	3 years
Computer software
Disclosure of detailed information about property, plant and equipment [line items]
Amortization method	Straight-line
Useful life	1 year

SUMMARY OF SIGNIFICANT ACCOUN_5

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Detail Textuals) - Property, plant and equipment subject to operating leases	Dec. 31, 2018CAD ($)
Disclosure of quantitative information about right-of-use assets [line items]
Committed future lease	$ 61,975,680
Minimum
Disclosure of quantitative information about right-of-use assets [line items]
Right of use assets and lease liabilities	1,500,000
Maximum
Disclosure of quantitative information about right-of-use assets [line items]
Right of use assets and lease liabilities	$ 2,000,000

SIGNIFICANT ACCOUNTING ESTIMA_2

SIGNIFICANT ACCOUNTING ESTIMATES AND JUDGMENTS (Detail Textuals)	12 Months Ended
	Dec. 31, 2018
Disclosure Of Accounting Judgements And Estimates [Abstract]
Finite-lived intangible assets, amortization method	straight-line basis

CHANGE IN ACCOUNTING POLICY (De

CHANGE IN ACCOUNTING POLICY (Details) - CAD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Profit or loss [abstract]
Cost of goods sold	$ 19,690,162	$ 7,680,234
Gross profit, before the unrealized gain on changes in fair value of biological assets	25,954,981	13,017,530
Fair value changes in biological assets included in inventory sold	17,301,866	8,929,308
Unrealized gain on changes in fair value of biological assets	(27,840,156)	(19,891,851)
Gross profit	36,493,271	23,980,073
New policy
Profit or loss [abstract]
Cost of goods sold	19,690,162	7,680,234
Amortization expensed to cost of sales	0	0
Gross profit, before the unrealized gain on changes in fair value of biological assets	25,954,981	13,017,530
Fair value changes in biological assets included in inventory sold	17,301,866	8,929,308
Unrealized gain on changes in fair value of biological assets	(27,840,156)	(19,891,851)
Gross profit	36,493,271	23,980,073
Original policy
Profit or loss [abstract]
Cost of goods sold	25,864,840	9,017,787
Amortization expensed to cost of sales	0	1,252,985
Gross profit, before the unrealized gain on changes in fair value of biological assets	19,780,303	10,426,992
Fair value changes in biological assets included in inventory sold	23,432,761	11,302,969
Unrealized gain on changes in fair value of biological assets	(40,145,729)	(24,856,050)
Gross profit	36,493,271	23,980,073
Impact of change
Profit or loss [abstract]
Cost of goods sold	(6,174,678)	(1,337,553)
Amortization expensed to cost of sales	0	(1,252,985)
Gross profit, before the unrealized gain on changes in fair value of biological assets	6,174,678	2,590,538
Fair value changes in biological assets included in inventory sold	(6,130,895)	(2,373,661)
Unrealized gain on changes in fair value of biological assets	12,305,573	4,964,199
Gross profit	$ 0	$ 0

CHANGE IN ACCOUNTING POLICY (_2

CHANGE IN ACCOUNTING POLICY (Details 1) - CAD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Cash flows from (used in) operating activities [abstract]
Biological assets expensed to cost of sales	$ 17,301,866	$ 8,929,309
Unrealized gain on changes in fair value of biological assets	27,840,156	19,891,851
Changes in non-working capital Inventory and biological assets	(13,857,744)	(3,529,772)
Cash flow used in operating activities	(20,446,751)	(501,546)
New policy
Cash flows from (used in) operating activities [abstract]
Biological assets expensed to cost of sales	17,301,866	8,929,308
Unrealized gain on changes in fair value of biological assets	(27,840,156)	(19,891,851)
Changes in non-working capital Inventory and biological assets	(13,857,744)	(3,529,771)
Cash flow used in operating activities	(20,446,751)	(501,546)
Original policy
Cash flows from (used in) operating activities [abstract]
Biological assets expensed to cost of sales	23,432,761	11,302,969
Unrealized gain on changes in fair value of biological assets	(40,145,729)	(24,856,050)
Changes in non-working capital Inventory and biological assets	(7,683,066)	(939,233)
Cash flow used in operating activities	(20,446,751)	(501,546)
Impact of change
Cash flows from (used in) operating activities [abstract]
Biological assets expensed to cost of sales	(6,130,895)	(2,373,661)
Unrealized gain on changes in fair value of biological assets	12,305,573	4,964,199
Changes in non-working capital Inventory and biological assets	(6,174,678)	(2,590,538)
Cash flow used in operating activities	$ 0	$ 0

ACQUISITION (Details)

ACQUISITION (Details) - CAD ($)	Dec. 31, 2018	Dec. 31, 2017	Mar. 06, 2017	Dec. 31, 2016
Assets
Plant and Equipment	$ 62,208,905	$ 33,963,685		$ 8,261,952
Elmcliffe Investments Inc.
Assets
Land			$ 484,507
Residential Buildings			571,000
Greenhouses and Equipment			4,215,192
Plant and Equipment			2,115,301
Vehicles			114,000
Total of assets at fair value			$ 7,500,000

ACQUISITION (Details 1)

ACQUISITION (Details 1)	Mar. 06, 2017CAD ($)
Acquisition-date fair value of total consideration transferred [abstract]
Cash Consideration	$ 6,500,000
Promissory note	1,000,000	[1]
Total	$ 7,500,000
[1]	As part of the consideration for the acquisition, a non-interest bearing promissory note was issued in the amount of $1,000,000 payable over 5 years in 5 consecutive annual payments of $200,000. The first payment of $200,000 was made in January 2018.

ACQUISITION (Details 2)

ACQUISITION (Details 2) - CAD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Disclosure of detailed information about borrowings [line items]
Non-Current portion of promissory note	$ 600,000	$ 800,000
Promissory note
Disclosure of detailed information about borrowings [line items]
Carrying amount, January 1	1,000,000	0
Issuance of promissory note	0	1,000,000
Repayment of promissory note	(200,000)	0
Carrying amount	800,000	1,000,000
less: Current portion of promissory note	(200,000)	(200,000)
Non-Current portion of promissory note	$ 600,000	$ 800,000

ACQUISITION (Detail Textuals)

ACQUISITION (Detail Textuals)	Mar. 06, 2017CAD ($)Payment	Jan. 31, 2018CAD ($)	Dec. 31, 2017CAD ($)
Acquisition-date fair value of total consideration transferred [abstract]
Aggregate purchase price for greenhouse assets	$ 7,500,000
Value of issuance promissory note for consideration	$ 1,000,000
Term of promissory note	5 years
Number of consecutive annual payments | Payment	5
Annual payments	$ 200,000
First payment made for promissory note		$ 200,000
Acquisition costs			$ 204,282

RESTRICTED CASH AND SHORT-TER_3

RESTRICTED CASH AND SHORT-TERM INVESTMENTS (Details) - CAD ($)		Dec. 31, 2018	Dec. 31, 2017
Restricted Cash And Short Term Investments [Abstract]
Short-term investment - GIC	[1]	$ 63,023,908	$ 201,538
Restricted cash - GIC held as collateral	[2]	100,000	100,765
Total restricted cash and short-term investments		$ 63,123,908	$ 302,303
[1]	The investment is a one-year GIC, redeemable every 30 days, held with a large Canadian financial institution at fixed interest rate of 1.6%. The GIC is redeemable without penalty after 30 days.
[2]	The Company has a letter of credit with a large Canadian financial institution for $100,000. A one-year GIC for $100,000 is held on collateral. The letter of credit has a one-year expiry from the date of issue and an automatic annual extension with 30 days' notice. The letter of credit is required as a covenant to the building lease agreement in the event of a default in lease payments.

RESTRICTED CASH AND SHORT-TER_4

RESTRICTED CASH AND SHORT-TERM INVESTMENTS (Detail Textuals)	12 Months Ended
	Dec. 31, 2018CAD ($)
Restricted Cash And Short Term Investments [Abstract]
Term of investment in GIC	One-year
Interest rate on investment	1.60%
Amount of letter of credit	$ 100,000
Amount held in GIC	$ 100,000
Letter of credit expiry period	One-year expiry from the date of issue and an automatic annual extension with 30 days' notice

INVENTORY AND BIOLOGICAL ASSE_3

INVENTORY AND BIOLOGICAL ASSETS (Details) - CAD ($)		12 Months Ended
		Dec. 31, 2018	Dec. 31, 2017
Disclosure of reconciliation of changes in biological assets [abstract]
Carrying amount, January 1	[1]	$ 9,843,690	$ 2,320,093
Seeds used		(9,656)	(979)	[1]
Changes in fair value less costs to sell due to biological transformation		27,840,156	19,891,851	[1]
Production costs capitalized		12,305,573	4,964,199	[1]
Transferred to inventory upon harvest		(39,477,184)	(17,331,474)	[1]
Carrying amount		$ 10,502,579	$ 9,843,690	[1]
[1]	Costs have been reallocated between production costs capitalized and changes in fair value less costs to sell due to biological transformation for the year ended December 31, 2017.

INVENTORY AND BIOLOGICAL ASSE_4

INVENTORY AND BIOLOGICAL ASSETS (Details 1) - CAD ($)	Dec. 31, 2018	Dec. 31, 2017		Dec. 31, 2016	[1]
Disclosure of detailed information about biological assets [abstract]
Carrying amount of seeds	$ 15,660	$ 25,316
Carrying amount of live plants	10,486,919	9,818,374
Carrying amount	$ 10,502,579	$ 9,843,690	[1]	$ 2,320,093
[1]	Costs have been reallocated between production costs capitalized and changes in fair value less costs to sell due to biological transformation for the year ended December 31, 2017.

INVENTORY AND BIOLOGICAL ASSE_5

INVENTORY AND BIOLOGICAL ASSETS (Details 2) - CAD ($)	Dec. 31, 2018	Dec. 31, 2017
Disclosure of detailed information about biological assets [line items]
Accessories	$ 52,458	$ 116,974
Packaging and supplies	443,520	137,500
Work-in-Progress	27,812,405	7,298,424
Finished Goods	7,081,107	3,406,124
Total Inventory	35,389,490	10,959,022
Dried Cannabis
Disclosure of detailed information about biological assets [line items]
Accessories	0	0
Packaging and supplies	0	0
Work-in-Progress	11,306,993	3,355,635
Finished Goods	4,095,610	1,279,339
Total Inventory	15,402,603	4,634,974
Extracts
Disclosure of detailed information about biological assets [line items]
Accessories	0	0
Packaging and supplies	0	0
Work-in-Progress	16,505,412	3,942,789
Finished Goods	2,985,497	2,126,785
Total Inventory	19,490,909	6,069,574
Other
Disclosure of detailed information about biological assets [line items]
Accessories	52,458	116,974
Packaging and supplies	443,520	137,500
Work-in-Progress	0	0
Finished Goods	0	0
Total Inventory	$ 495,978	$ 254,474

INVENTORY AND BIOLOGICAL ASSE_6

INVENTORY AND BIOLOGICAL ASSETS (Detail Textuals)	12 Months Ended
	Dec. 31, 2018CAD ($)Grams$ / shares	Dec. 31, 2017CAD ($)Grams
Disclosure of detailed information about biological assets [line items]
Percentage of weighted average expected yield harvest	58.00%	52.00%
Average number of days point of propagation harvest	112 days
Biological assets yield net of waste | Grams	13,926,974	1,911,972
Weighted average selling price	$ 1.54
Percentage of decrease in selling price of fair value in biological assets	10.00%
Decrease in fair value of the biological assets by perecntage of decrease in selling prices | $	$ 2,071,058	$ 1,261,124
Percentage of decrease in fair value of biological assets	10.00%
Decrease in fair value of the biological assets by perecntage of decrease in yield | $	$ 1,050,258	$ 574,665
Harvest cannabis
Disclosure of detailed information about biological assets [line items]
Weighted average selling price	$ 4.50
Harvest cannabis trim
Disclosure of detailed information about biological assets [line items]
Weighted average selling price	$ 1.28
Dried Cannabis
Disclosure of detailed information about biological assets [line items]
Quantity of inventory | Grams	4,471,032	626,935
Extracts
Disclosure of detailed information about biological assets [line items]
Quantity of inventory | Grams	6,887,849	977,186
Minimum
Disclosure of detailed information about biological assets [line items]
Net selling price of biological asset per gram	$ 2.92
Selling costs per gram	0.61
Maximum
Disclosure of detailed information about biological assets [line items]
Net selling price of biological asset per gram	12
Selling costs per gram	$ 2.46

PROPERTY AND EQUIPMENT (Details

PROPERTY AND EQUIPMENT (Details) - CAD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Disclosure of detailed information about property, plant and equipment [line items]
Balance	$ 33,963,685	$ 8,261,952
Additions	33,019,302	31,493,811
Amortization	693,323	385,950
Disposals		(136,235)
Balance	62,208,905	33,963,685
Accumulated Amortization
Disclosure of detailed information about property, plant and equipment [line items]
Balance	(5,655,843)	(3,052,512)
Amortization	(4,774,082)	(2,603,331)
Balance	(10,429,925)	(5,655,843)
Carrying Amounts
Disclosure of detailed information about property, plant and equipment [line items]
Balance	33,963,685	5,209,440
Balance	62,208,905	33,963,685
Land
Disclosure of detailed information about property, plant and equipment [line items]
Balance	484,507	0
Additions	675,333	484,507
Disposals		0
Balance	1,159,840	484,507
Land | Accumulated Amortization
Disclosure of detailed information about property, plant and equipment [line items]
Balance	0	0
Amortization	0	0
Balance	0	0
Land | Carrying Amounts
Disclosure of detailed information about property, plant and equipment [line items]
Balance	484,507	0
Balance	1,159,840	484,507
Leasehold Improvements
Disclosure of detailed information about property, plant and equipment [line items]
Balance	2,966,924	2,796,356
Additions	3,360,622	170,568
Disposals		0
Balance	6,327,546	2,966,924
Leasehold Improvements | Accumulated Amortization
Disclosure of detailed information about property, plant and equipment [line items]
Balance	(902,800)	(612,441)
Amortization	(424,341)	(290,359)
Balance	(1,327,141)	(902,800)
Leasehold Improvements | Carrying Amounts
Disclosure of detailed information about property, plant and equipment [line items]
Balance	2,064,124	2,183,915
Balance	5,000,405	2,064,124
Buildings, Greenhouse and Improvements
Disclosure of detailed information about property, plant and equipment [line items]
Balance	16,438,144	0
Additions	25,158,539	16,528,144
Disposals		(90,000)
Balance	41,596,683	16,438,144
Buildings, Greenhouse and Improvements | Accumulated Amortization
Disclosure of detailed information about property, plant and equipment [line items]
Balance	(293,922)	0
Amortization	(1,116,348)	(293,922)
Balance	(1,410,270)	(293,922)
Buildings, Greenhouse and Improvements | Carrying Amounts
Disclosure of detailed information about property, plant and equipment [line items]
Balance	16,144,222	0
Balance	40,186,413	16,144,222
Equipment
Disclosure of detailed information about property, plant and equipment [line items]
Balance	18,734,488	4,815,487
Additions	2,501,273	13,965,236
Disposals		(46,235)
Balance	21,235,761	18,734,488
Equipment | Accumulated Amortization
Disclosure of detailed information about property, plant and equipment [line items]
Balance	(3,801,511)	(1,968,502)
Amortization	(2,661,805)	(1,833,009)
Balance	(6,463,316)	(3,801,511)
Equipment | Carrying Amounts
Disclosure of detailed information about property, plant and equipment [line items]
Balance	14,932,977	2,846,985
Balance	14,772,445	14,932,977
Other
Disclosure of detailed information about property, plant and equipment [line items]
Balance	995,465	650,109
Additions	1,323,535	345,356
Disposals		0
Balance	2,319,000	995,465
Other | Accumulated Amortization
Disclosure of detailed information about property, plant and equipment [line items]
Balance	(657,610)	(471,569)
Amortization	(571,588)	(186,041)
Balance	(1,229,198)	(657,610)
Other | Carrying Amounts
Disclosure of detailed information about property, plant and equipment [line items]
Balance	337,855	178,540
Balance	$ 1,089,802	$ 337,855

PROPERTY AND EQUIPMENT (Detail

PROPERTY AND EQUIPMENT (Detail Textuals) - CAD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Property, plant and equipment [abstract]
Amortization	$ 693,323	$ 385,950
Cost of goods sold include amortization	$ 1,948,666	$ 1,252,985

IMPAIRMENT (Detail Textuals)

IMPAIRMENT (Detail Textuals)	12 Months Ended
	Dec. 31, 2018CAD ($)
Disclosure of impairment loss and reversal of impairment loss [abstract]
Impairment loss	$ 988,160
Reduction in carrying value of intangible assets

FINANCIAL ASSETS (Details)

FINANCIAL ASSETS (Details) - CAD ($)		12 Months Ended
		Dec. 31, 2018	Dec. 31, 2017
Disclosure of financial assets [line items]
Carrying amount, January 1		$ 0	$ 0
Convertible debenture	[1]	750,000	0
Received Warrants on purchase of shares	[2]	151,350	0
Carrying amount		$ 901,350	$ 0
[1]	On December 20, 2018, the Company made an additional investment of $750,000 in GWAH and received unsecured interest bearing convertible debentures and 150,000 warrants exercisable to purchase 150,000 shares of GWAH at $2 per share.
[2]	As part of the issue of shares (see note 18 (vi)), the Company received 6,400,000 warrants exercisable to purchase 6,400,000 shares of Cannatrek at $0.40 a share. The total considerations paid was allocated to common shares and warrants in the amounts of $5,887,050 and $151,350.

FINANCIAL ASSETS (Detail Textua

FINANCIAL ASSETS (Detail Textuals) - GWAH - Issuance of warrants - CAD ($)	1 Months Ended	12 Months Ended
	Dec. 20, 2018	Dec. 31, 2018
Disclosure of financial assets [line items]
Issuance of warrants		$ 151,350
Percentage of warrants expected dividend yield		0.00%
Warrants average expected volatility		80.00%
Warrants average risk-free rate		2.09%
Warrants share price per share		$ 0.19
Percentage of warrant forfeiture rate		0.00%
Warrant expected life		1 year 2 months 1 day
Percentage of decrease In volatility rate		5.00%
Decrease in volatility valuation of warrants		$ 19,119
Decrease in valuation of warrants		$ 19,640
Percentage of decrease in valuation of warrants		5.00%
Issuance of warrant exercisable	$ 150,000
Common stock share purchase	150,000
Common stock price per share	$ 2
Additional investment	$ 750,000
Issuance of warrant exercisable		$ 6,400,000
Common stock share purchase		6,400,000
Common stock price per share		$ 0.40
Considerations paid allocated to common shares		$ 5,887,050
Considerations paid allocated to warrants		$ 151,350

MORTGAGE (Details)

MORTGAGE (Details) - CAD ($)	1 Months Ended	12 Months Ended
	Feb. 14, 2018	Dec. 31, 2018	Dec. 31, 2017
Disclosure of detailed information about borrowings [line items]
Less: current portion of mortage		$ 3,790,610
Non-current portion of mortgage		9,457,876
Mortgage
Disclosure of detailed information about borrowings [line items]
Carrying amount, January 1		0	$ 0
Advance of mortgage financing (net of costs)		9,529,638	0
Second advance of mortgage financing (net of costs)	$ 10,000,000	3,750,000	0
Accretion expense		208,842	0
Mortgage payments		(239,994)	0
Carrying amount		13,248,486	0
Less: current portion of mortage		(3,790,610)	0
Non-current portion of mortgage		$ 9,457,876	$ 0

MORTGAGE (Detail Textuals)

MORTGAGE (Detail Textuals) - Mortgage - CAD ($)	1 Months Ended		12 Months Ended
	Dec. 27, 2018	Feb. 14, 2018	Dec. 31, 2018	Dec. 31, 2017
Disclosure of detailed information about borrowings [line items]
Amount of mortgage financing	$ 3,750,000	$ 15,000,000
Advance of mortgage financing		$ 10,000,000	$ 3,750,000	$ 0
Term of advances	P1Y	P2Y
Amortization period of advances	19 years 2 months	20 years
Annual interest rate	5.45%	6.03%
Borrowing costs incurred		$ 470,365
Effective interest rate	5.60%	9.09%

SHARE CAPITAL (Details)

SHARE CAPITAL (Details) - CAD ($)		Mar. 09, 2017	Mar. 06, 2017	Nov. 30, 2017	Sep. 19, 2017	Aug. 17, 2017	Dec. 31, 2018		Dec. 31, 2017
Balance							$ 70,868,418		$ 10,468,249
February 2017 Private Placement				$ 1,552,535					26,188,200
March 2017 Share issuance on exercise of convertible debt			$ 600,000						877,497
March 2017 Exercise of warrants		$ 545,919			$ 4,257	$ 23,099,955			1,300,000
March 2017 Share issuance on exercise of convertible debt due on demand									1,068,161
March 2017 Share issuance as partial consideration for Warrant Financing									150,000
April 2017 Share issuance in lieu of services									200,000
August 2017 Share issuance on automatic conversion of convertible debt			$ 600,000						4,062,606
September 2017 Exercise of warrants							1,239,875		5,459
November 27, 2017 Exercise of stock options							1,830,691		50,000
November 30, 2017 Private Placement				$ 1,552,535					18,447,465
Exercise of broker warrants							2,113,611		27,008
Units Issued							$ 103,470,364
Balance (in shares)		1,000,000		4,000,000	4,963	2,885,354	567,406
Balance							$ 174,025,794		$ 70,868,418
Share Capital
Balance (in shares)							90,906,265		67,995,919
Balance							$ 104,824,215		$ 53,916,169
February 2017 Private Placement (in shares)	[1]								510,000
February 2017 Private Placement	[1]								$ 1,020,000
March 2017 Share issuance on exercise of convertible debt (in shares)	[2]								644,264
March 2017 Share issuance on exercise of convertible debt	[2]								$ 877,497
March 2017 Exercise of warrants (in shares)	[3]								1,000,000
March 2017 Exercise of warrants	[3]								$ 1,845,919
March 2017 Share issuance on exercise of convertible debt due on demand (in shares)	[4]								1,068,161
March 2017 Share issuance on exercise of convertible debt due on demand	[4]								$ 1,068,161
March 2017 Share issuance as partial consideration for Warrant Financing (in shares)	[5]								75,000
March 2017 Share issuance as partial consideration for Warrant Financing	[5]								$ 150,000
April 2017 Share issuance in lieu of services (in shares)	[6]								100,000
April 2017 Share issuance in lieu of services	[6]								$ 200,000
August 2017 Share issuance on automatic conversion of convertible debt (in shares)	[7]								2,885,354
August 2017 Share issuance on automatic conversion of convertible debt	[7]								$ 4,062,606
August 2017 Share issuance on automatic conversion of Special Warrants (in shares)	[8]								12,584,100
August 2017 Share issuance on automatic conversion of Special Warrants	[8]								$ 23,099,955
September 2017 Exercise of warrants (in shares)							1,127,159	[9]	4,963	[10]
September 2017 Exercise of warrants							$ 2,206,754	[9]	$ 9,716	[10]
Exercise of stock options (in shares)							798,101	[11]	25,000	[12]
November 27, 2017 Exercise of stock options							$ 3,445,256	[11]	$ 88,376	[12]
November 30, 2017 Private Placement (in shares)	[13]								4,000,000
November 30, 2017 Private Placement	[13]								$ 18,447,465
Exercise of broker warrants (in shares)							719,556	[14]	13,504	[15]
Exercise of broker warrants							$ 2,862,769	[14]	$ 38,351	[15]
Units Issued (in shares)	[16]						12,057,405
Units Issued	[16]						$ 93,722,429
Balance (in shares)							105,608,486		90,906,265
Balance							$ 207,061,423		$ 104,824,215
[1]	On February 17, 2017, the Company issued, on a private placement basis, 510,000 common shares of the Company at a price of $2.00 per share for gross proceeds of $1,020,000. No broker fees were paid in respect of the 510,000 common shares issued.
[2]	On March 6, 2017, $600,000 of convertible debt with a total carrying value of $768,807 and $108,690 in accrued interest were converted into common shares at $1.10 per share resulting in the issuance of 644,264 common shares.
[3]	On March 9, 2017, 2 warrants were exercised to purchase 1,000,000 common shares at $1.30 per share for gross proceeds of $1,300,000. The carrying value of the warrants were $545,919.
[4]	On March 15, 2017, $1,000,000 of due on demand convertible debt and $68,161 in accrued interest were converted into common shares at $1.00 per share resulting in the issuance of 1,068,161 common shares.
[5]	As consideration for the special warrant subscription, the Company issued 75,000 common shares to the Agent on March 16, 2017. The value of the shares was measured by reference to the fair value of the common shares of the Company at the grant date. The fair value at the grant date was $2.00 per share.
[6]	On April 28, 2017, 100,000 common shares were issued as consideration for management fees to related parties. The shares were valued at $2.00 per share, as determined by the value of the services received and invoices.
[7]	On August 17, 2017, $3,040,919 of convertible debt and related derivative liability with a total carrying value of $3,929,639 and $132,967 in accrued interest were converted into common shares, in connection with the Company listing on the Canadian Securities Exchange, at $1.10 per share resulting in the issuance of 2,885,354 common shares.
[8]	On August 17, 2017, 12,584,100 Special Warrants were automatically converted into 12,584,100 common shares at $2 per share at a carrying value of $23,099,955, in connection with the Company listing on the Canadian Securities Exchange. There were no proceeds from the conversion of Special Warrants to common shares.
[9]	During the twelve months ended December 31, 2018, 1,127,159 warrants were exercised to purchase 1,127,159 common shares at $1.10 per share for gross proceeds of $1,239,875. The carrying value of the warrants was $966,879.
[10]	On September 19, 2017, 4,963 warrants were exercised to purchase 4,963 common shares at $1.10 per share for gross proceeds $5,459. The carrying value of the warrants was $4,257.
[11]	During the twelve months ended December 31, 2018, 798,101 were exercised at an average strike price of $2.29 per share for gross proceeds of $1,830,690. The carrying value of the options was $1,614,565.
[12]	On November 27, 2017, 25,000 stock options were exercised at $2.00 per share for gross proceeds of $50,000.
[13]	On November 30, 2017, the Company issued, on a private placement basis, 4,000,000 common shares at $5.00 per share for the gross proceeds of $20,000,000. The Company's Agent for the private placement was paid an Agent's Fee of $1,100,000 and was issued Broker Warrants equaling 5.5% of the number of common shares issued as part of the private placement. Total transaction costs for the private placement were $1,552,535.
[14]	During the twelve months ended December 31, 2018, 567,406 broker warrants were exercised to purchase 567,406 common shares at $2.00 per share for gross proceeds of $1,134,812. The carrying value of the warrants was $476,508. During the twelve months ended December 31, 2018, 121,000 broker warrants were exercised to purchase 121,000 common shares at $5.00 broker warrants per share for gross proceeds of $605,000. The carrying value of the warrants was $218,207. During the twelve months ended December 31, 2018, 31,150 broker warrants were exercised to purchase 31,150 common shares at $12.00 per share for gross proceeds of $373,800. The carrying value of the warrants was $54,442.
[15]	During the year ended December 31, 2017, 13,504 warrants were exercised to purchase 13,504 common shares at $2.00 per share for gross proceeds $27,008. The carrying value of the warrants was $11,343.
[16]	On June 5, 2018 the Company issued, on a bought deal basis, 11,155,000 units at $9.00 per unit for gross proceeds of $100,395,000. There were transaction costs for the bought deal of $6,156,239. Each unit issued consisted of one common share and one-half of one common share purchase warrant (see Note 15(v)). The total net proceeds of the bought deal were allocated to Common Share Capital and Warrants in the amounts of $84,490,826 and $9,747,935 respectively. On October 17, 2018, the Company finalized a partnership with Kindred Partners Inc., a wholly-owned subsidiary of Breakthru Beverage Group ("Breakthru"). Breakthru purchased 902,405 common shares of the Company at $10.23 per share for gross proceeds of $9,231,600. In addition, Breakthru was issued warrants to purchase up to an additional 2,000,000 common shares (see Note 15(vi)).

SHARE CAPITAL (Details 1)

SHARE CAPITAL (Details 1) - CAD ($)		12 Months Ended
		Dec. 31, 2018	Dec. 31, 2017
Numerator - basic and diluted earnings per share:
Net (loss) income and comprehensive (loss) income		$ (13,553,616)	$ 6,885,430
Denominator - basic earnings per share:
Weighted average number of shares - basic		99,282,045	76,876,971
Denominator - diluted earnings per share:
Stock Options	[1]	0	1,218,015
Warrants	[1]	0	2,431,119
Weighted average number of shares - diluted		99,282,045	80,526,105
Earnings (loss) per share - basic		$ (0.14)	$ 0.09
Earnings (loss) per share - diluted		$ (0.14)	$ 0.09
[1]	Stock options and warrants were excluded from the weighted average number of shares as they were anti-dilutive for the year ended December 31, 2018.

SHARE CAPITAL (Detail Textuals)

SHARE CAPITAL (Detail Textuals)	Jun. 05, 2018CAD ($)$ / sharesshares	Mar. 15, 2017CAD ($)$ / sharesshares	Mar. 09, 2017CAD ($)Warrants$ / sharesshares	Mar. 06, 2017CAD ($)$ / sharesshares	Oct. 17, 2018USD ($)shares	Nov. 30, 2017CAD ($)$ / sharesshares	Nov. 27, 2017CAD ($)$ / sharesshares	Sep. 19, 2017CAD ($)Warrants$ / sharesshares	Aug. 17, 2017CAD ($)$ / sharesshares	Feb. 17, 2017CAD ($)$ / sharesshares	Dec. 31, 2018CAD ($)Warrants$ / sharesshares	Dec. 31, 2017CAD ($)Warrants$ / sharesshares	Oct. 17, 2018$ / shares	Apr. 28, 2017$ / sharesshares	Mar. 16, 2017$ / sharesshares
Number of common share issue | shares			1,000,000			4,000,000		4,963	2,885,354	510,000	567,406			100,000	75,000
Subscription price per common share | $ / shares			$ 1.30							$ 2		$ 2		$ 2	$ 2
Proceeds from issuing shares			$ 1,300,000			$ 20,000,000	$ 50,000	$ 5,459		$ 1,020,000	$ 1,239,875	$ 27,008
Value of convertible debt				$ 600,000								$ 4,062,606
Carying amount of convertible debt				768,807
Accrued interest		$ 68,161		$ 108,690					$ 132,967
Conversion price per share | $ / shares						$ 5
Number of common shares converted | shares		1,068,161		644,264
Number of warrant exercise | Warrants			2					4,963			1,127,159	13,504
Carrying amount of warrants			$ 545,919					$ 4,257	23,099,955			$ 1,300,000
Due on demand convertible debt		$ 1,000,000
Amount of convertible debt									3,040,919
Derivative liability at carrying value									$ 3,929,639
Number of warrants | shares									12,584,100
Warrants converted into common shares | shares								4,963	12,584,100		1,127,159	13,504
Conversion price of warrant | $ / shares								$ 1.10	$ 2		$ 1.10
Conversion price of convertible debt | $ / shares		$ 1		$ 1.10					$ 1.10
Number of stock options exercised | shares							25,000				798,101
Exercise price share options | $ / shares							$ 2				$ 2
Agent's Fee						$ 1,100,000
Percentage of broker warrant						5.50%
Costs for the private placement						$ 1,552,535						$ 26,188,200
Purchase of common share | shares											1,127,159
Average exercise price | $ / shares											$ 2.29
Carrying value of option											$ 1,614,565
Gross proceeds of exercise price											$ 1,830,690
Agent Warrants Exercised | shares											567,406
Proceeds from issuance of common shares											$ 1,134,812
Exercise of broker warrants | shares											567,406
Exercise purchase of broker warrants | shares											567,406
Exercise price of broker warrants | $ / shares											$ 2
Proceeds of exercised broker warrants											$ 1,134,812
Carrying value of warrants											$ 476,508
Exercise of broker warrants | shares											121,000
Exercise purchase of broker warrants | shares											121,000
Exercise price of broker warrants | $ / shares											$ 5
Proceeds of exercised broker warrants											$ 605,000
Carrying value of warrants											$ 218,207
Exercise of broker warrants | shares											31,150
Exercise purchase of broker warrants | shares											31,150
Exercise price of broker warrants | $ / shares											$ 12
Proceeds of exercised broker warrants											$ 373,800
Carrying value of warrants											$ 54,443	$ 11,343
Bought deal basis of units | shares	11,155,000
Bought deal basis price per unit | $ / shares	$ 9
Gross proceeds of bought deal basis	$ 100,395,000
Transaction cost of bought deal	6,156,239
Common share capital	84,490,826
Share warrants	$ 9,747,935
Breakthru Beverage Group (Breakthru)
Exercise price share options | $ / shares													$ 10.23
Purchase of common share | shares					902,405
Gross proceeds of exercise price					$ 9,231,603
Purchase of warrant | shares					2,000,000

STOCK OPTION PLAN (Details)

STOCK OPTION PLAN (Details)	12 Months Ended
	Dec. 31, 2018CAD ($)Share	Dec. 31, 2017CAD ($)Share
Options issued
Options issued at the begining | Share	3,526,000	0
Options granted | Share	2,854,500	3,670,500
Options forfeited | Share	(1,467,836)	(119,500)
Options exercised | Share	(798,101)	(25,000)
Options issued at the ending | Share	4,114,563	3,526,000
Weighted Average exercise price
Options issued at the begining | $	$ 3.45	$ 0
Options granted | $	8.17	3.4
Options forfeited | $	5.38	2.11
Options exercised | $	2.29	2
Options issued at the ending | $	$ 7.59	$ 3.45

STOCK OPTION PLAN (Details 1)

STOCK OPTION PLAN (Details 1)	Dec. 31, 2018CAD ($)ShareYear	Dec. 31, 2017CAD ($)Share	Dec. 31, 2016Share
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number of options outstanding | Share	4,114,563	3,526,000	0
Weighted Average Remaining Contractual Life (years) | Year	9.3
Options Outstanding, Exercise Price per share	$ 7.59
Number Exercisable | Share	1,088,850
Options Exercisable, Exercise Price per share	$ 6.26	$ 3.45
$0.00 - $3.50
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number of options outstanding | Share	1,270,722
Weighted Average Remaining Contractual Life (years) | Year	8.7
Number Exercisable | Share	520,702
$0.00 - $3.50 | Minimum
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Options Outstanding, Exercise Price per share	$ 0
Options Exercisable, Exercise Price per share	0
$0.00 - $3.50 | Maximum
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Options Outstanding, Exercise Price per share	3.50
Options Exercisable, Exercise Price per share	$ 3.50
$3.51 - $6.72
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number of options outstanding | Share	429,841
Weighted Average Remaining Contractual Life (years) | Year	9.2
Number Exercisable | Share	46,831
$3.51 - $6.72 | Minimum
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Options Outstanding, Exercise Price per share	$ 3.51
Options Exercisable, Exercise Price per share	3.51
$3.51 - $6.72 | Maximum
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Options Outstanding, Exercise Price per share	6.72
Options Exercisable, Exercise Price per share	$ 6.72
$6.73 - $9.00
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number of options outstanding | Share	634,000
Weighted Average Remaining Contractual Life (years) | Year	9.3
Number Exercisable | Share	96,317
$6.73 - $9.00 | Minimum
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Options Outstanding, Exercise Price per share	$ 6.73
Options Exercisable, Exercise Price per share	6.73
$6.73 - $9.00 | Maximum
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Options Outstanding, Exercise Price per share	9
Options Exercisable, Exercise Price per share	$ 9
$9.01 - $11.88
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number of options outstanding | Share	1,780,000
Weighted Average Remaining Contractual Life (years) | Year	9.7
Number Exercisable | Share	425,000
$9.01 - $11.88 | Minimum
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Options Outstanding, Exercise Price per share	$ 9.01
Options Exercisable, Exercise Price per share	9.01
$9.01 - $11.88 | Maximum
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Options Outstanding, Exercise Price per share	11.88
Options Exercisable, Exercise Price per share	$ 11.88

STOCK OPTION PLAN (Details 2)

STOCK OPTION PLAN (Details 2)	12 Months Ended
	Dec. 31, 2018CAD ($)Year
Disclosure of terms and conditions of share-based payment arrangement [line items]
Expected dividend yield
Forfeiture rate	6.00%
Exercise price (per share)	$ 9.28
Minimum
Disclosure of terms and conditions of share-based payment arrangement [line items]
Risk-free interest rate	2.30%
Expected life of options (years) | Year	2.5
Expected annualized volatility	79.00%
Exercise price (per share)	$ 6.70
Maximum
Disclosure of terms and conditions of share-based payment arrangement [line items]
Risk-free interest rate	2.82%
Expected life of options (years) | Year	6.4
Expected annualized volatility	87.00%
Exercise price (per share)	$ 11.88

STOCK OPTION PLAN (Detail Textu

STOCK OPTION PLAN (Detail Textuals) - CAD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Disclosure of terms and conditions of share-based payment arrangement [abstract]
Value of exercise of options	$ 9.28
Share-based compensation expense	$ 8,056,451	$ 2,310,678

RESERVE FOR WARRANTS (Details)

RESERVE FOR WARRANTS (Details) - CAD ($)		12 Months Ended
		Dec. 31, 2018		Dec. 31, 2017	Dec. 31, 2016
Disclosure Of Reserves For Warrants [Line Items]
Number of Warrants		6,181,507		2,450,722	1,654,801
Number of common shares to be issued on exercise of warrants		7,181,506		3,450,721	3,654,798
Amount		$ 11,393,687		$ 3,361,789	$ 3,027,398
Weighted average exercise price		$ 9.6		$ 1.56	$ 1.21
Weighted average remaining life in years		1 year 4 months 17 days		2 years 2 months 1 day	1 year 9 months 4 days
Warrant | February 2017 Private Placement
Disclosure Of Reserves For Warrants [Line Items]
Number of Warrants				12,584,100
Number of common shares to be issued on exercise of warrants				12,584,100
Amount				$ 23,099,955
Weighted average exercise price				$ 2
Warrant | February 2017 Warrants issued as partial consideration for Private Placement
Disclosure Of Reserves For Warrants [Line Items]
Number of Warrants				594,390
Number of common shares to be issued on exercise of warrants				594,390
Amount				$ 499,169
Weighted average exercise price				$ 2
Weighted average remaining life in years				1 year 1 month 17 days
Warrant | March 2017 Exercise of warrants
Disclosure Of Reserves For Warrants [Line Items]
Number of Warrants				(2)
Number of common shares to be issued on exercise of warrants				(1,000,000)
Amount				$ (545,919)
Weighted average exercise price				$ 1.3
Warrant | August 2017 Share issuance on automatic conversion of Special Warrants
Disclosure Of Reserves For Warrants [Line Items]
Number of Warrants				(12,584,100)
Number of common shares to be issued on exercise of warrants				(12,584,100)
Amount				$ (23,099,955)
Weighted average exercise price				$ 2
Warrant | September 2017 Exercise of warrants
Disclosure Of Reserves For Warrants [Line Items]
Number of Warrants				(4,963)
Number of common shares to be issued on exercise of warrants				(4,963)
Amount				$ (4,257)
Weighted average exercise price				$ 1.1
Weighted average remaining life in years				2 years 7 months 21 days
Warrant | November 30, 2017 Warrants issued as partial consdieration for Private Placement
Disclosure Of Reserves For Warrants [Line Items]
Number of Warrants				220,000
Number of common shares to be issued on exercise of warrants				220,000
Amount				$ 396,741
Weighted average exercise price				$ 5
Weighted average remaining life in years				1 year 11 months 1 day
Warrant | Exercise of broker warrants
Disclosure Of Reserves For Warrants [Line Items]
Number of Warrants		(567,406)	[1]	(13,504)
Number of common shares to be issued on exercise of warrants		(567,406)	[1]	(13,504)
Amount		$ (476,508)	[1]	$ (11,343)
Weighted average exercise price		$ 2	[1]	$ 2
Weighted average remaining life in years				1 year 1 month 17 days
Warrant | Exercise of warrants
Disclosure Of Reserves For Warrants [Line Items]
Number of Warrants	[2]	(1,127,159)
Number of common shares to be issued on exercise of warrants	[2]	(1,127,159)
Amount	[2]	$ (966,879)
Weighted average exercise price	[2]	$ 1.1
Warrant | Exercise of broker warrants
Disclosure Of Reserves For Warrants [Line Items]
Number of Warrants	[3]	(121,000)
Number of common shares to be issued on exercise of warrants	[3]	(121,000)
Amount	[3]	$ (218,207)
Weighted average exercise price	[3]	$ 5
Warrant | Exercise of broker warrants
Disclosure Of Reserves For Warrants [Line Items]
Number of Warrants	[4]	(31,150)
Number of common shares to be issued on exercise of warrants	[4]	(31,150)
Amount	[4]	$ (54,443)
Weighted average exercise price	[4]	$ 12
Warrant | Warrants issued as partial consideration of Bought Deal
Disclosure Of Reserves For Warrants [Line Items]
Number of Warrants	[5]	5,577,500
Number of common shares to be issued on exercise of warrants	[5]	5,577,500
Amount	[5]	$ 9,747,935
Weighted average exercise price	[5]	$ 12
Weighted average remaining life in years		1 year 5 months 5 days
[1]	During the year ended December 31, 2018, 567,406 broker warrants were exercised to purchase 567,406 common shares at $2.00 per share for gross proceeds of $1,134,812. The carrying value of the warrants was $476,508.
[2]	During the year ended December 31, 2018, 1,127,159 warrants were exercised to purchase 1,127,159 common shares at $1.10 per share for gross proceeds of $1,239,875. The carrying value of the warrants was $966,879.
[3]	During the year ended December 31, 2018, 121,000 broker warrants were exercised to purchase 121,000 common shares at $5.00 per share for gross proceeds of $605,000. The carrying value of the warrants was $218,207.
[4]	During the year ended December 31, 2018, 31,150 broker warrants were exercised to purchase 31,150 common shares at $12.00 per share for gross proceeds of $373,800. The carrying value of the warrants was $54,443.
[5]	On June 5, 2018, the Company issued, on a bought deal basis, 11,155,000 units at $9.00 per unit for gross proceeds of $100,395,000. Each unit consisted of one common share and one-half of one common share purchase warrant. Each Warrant is exercisable to acquire one Common Share at an exercise price of $12.00 per share, subject to adjustment in certain events, until June 5, 2020. In the event that the daily volume weighted average trading price of the Common Shares exceeds $18.00 for 10 consecutive trading days on the Toronto Stock Exchange ("TSX"), the Company has the right to accelerate the expiry date of the warrants upon providing not less than 15 trading days' notice of such acceleration. The warrants were valued at $9,747,935 at the grant date using a weighted average value derived from a Black-Scholes pricing model that is affected by the Company's stock price as well as assumptions regarding a number of highly complex and subjective variables. Transaction costs and agent's fee of $636,793 were netted against the warrants. The following assumptions were used in the valuation: a) expected dividend yield of 0%; b) average expected volatility of 68 - 89%; c) average risk-free rate of 1.26 - 1.91%; d) share price of $8.89; e) forfeiture rate of 0% and; f) expected life of 0.25 - 2 years.

RESERVE FOR WARRANTS (Detail Te

RESERVE FOR WARRANTS (Detail Textuals)	Jun. 05, 2018CAD ($)CAD_per_shares$ / sharesshares	Mar. 09, 2017CAD ($)	Nov. 30, 2017CAD ($)	Nov. 27, 2017CAD ($)	Sep. 19, 2017CAD ($)$ / shares	Aug. 17, 2017CAD ($)$ / shares	Feb. 17, 2017CAD ($)	Dec. 31, 2018CAD ($)YearCAD_per_sharesWarrants$ / sharesshares	Dec. 31, 2017CAD ($)
Disclosure Of Reserves For Warrants [Line Items]
Number of warrant exercise | Warrants								1,127,159
Purchase of common share | shares								1,127,159
Conversion price of warrant | $ / shares					$ 1.10	$ 2		$ 1.10
Proceeds from issuing shares		$ 1,300,000	$ 20,000,000	$ 50,000	$ 5,459		$ 1,020,000	$ 1,239,875	$ 27,008
Carrying amount of warrants		$ 545,919			$ 4,257	$ 23,099,955			1,300,000
Exercise of broker warrants | shares								567,406
Exercise purchase of broker warrants | shares								567,406
Exercise price of broker warrants | $ / shares								$ 2
Proceeds of exercised broker warrants								$ 1,134,812
Carrying value of warrants								$ 476,508
Exercise of broker warrants | shares								121,000
Exercise purchase of broker warrants | shares								121,000
Exercise price of broker warrants | $ / shares								$ 5
Proceeds of exercised broker warrants								$ 605,000
Carrying value of warrants								$ 218,207
Exercise of broker warrants | shares								31,150
Exercise purchase of broker warrants | shares								31,150
Exercise price of broker warrants | $ / shares								$ 12
Proceeds of exercised broker warrants								$ 373,800
Carrying value of warrants								$ 54,443	$ 11,343
Bought deal basis of units | shares	11,155,000
Bought deal basis price per unit | $ / shares	$ 9
Gross proceeds of bought deal basis	$ 100,395,000
Warrant exercise price | CAD_per_shares	12							9.30
Weighted average trading price of common shares | $ / shares	$ 18
Number of trading days	10 days
Share warrants	$ 9,747,935
Transaction fees against warrant	$ 636,793
Expected dividend yield
Share price								$ 9.28
Minimum
Disclosure Of Reserves For Warrants [Line Items]
Average expected volatility								79.00%
Risk-free interest rate								2.30%
Share price								$ 6.70
Expected life of options (years) | Year								2.5
Maximum
Disclosure Of Reserves For Warrants [Line Items]
Average expected volatility								87.00%
Risk-free interest rate								2.82%
Share price								$ 11.88
Expected life of options (years) | Year								6.4
Warrant
Disclosure Of Reserves For Warrants [Line Items]
Expected dividend yield								$ 0
Share price								$ 8.89
Forfeiture rate								0.00%
Warrant | Minimum
Disclosure Of Reserves For Warrants [Line Items]
Average expected volatility								68.00%
Risk-free interest rate								1.26%
Expected life of options (years) | Year								0.25
Warrant | Maximum
Disclosure Of Reserves For Warrants [Line Items]
Average expected volatility								89.00%
Risk-free interest rate								1.91%
Expected life of options (years) | Year								2

COMMITMENTS (Details)

COMMITMENTS (Details)	12 Months Ended
	Dec. 31, 2018CAD ($)
Commitment [Line Items]
Leases	$ 64,687,912
Marketing	2,545,461
Total	67,233,373
2019
Commitment [Line Items]
Leases	4,055,054
Marketing	2,545,461
Total	6,600,515
2020
Commitment [Line Items]
Leases	3,436,577
Marketing	0
Total	3,436,577
2021
Commitment [Line Items]
Leases	3,407,940
Marketing	0
Total	3,407,940
2022
Commitment [Line Items]
Leases	3,407,940
Marketing	0
Total	3,407,940
2023
Commitment [Line Items]
Leases	3,382,177
Marketing	0
Total	3,382,177
Beyond
Commitment [Line Items]
Leases	46,998,224
Marketing	0
Total	$ 46,998,224

COMMITMENTS (Detail Textuals)

COMMITMENTS (Detail Textuals)	Mar. 07, 2018CAD ($)YearSquarefoot
Commitments and Contingencies Disclosure [Abstract]
Area of Greenhouse | Squarefoot	450,000
Aggregated lease and maintenance payments | $	$ 61,975,680
Term for aggregated lease and maintenance payments | Year	20

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Detail Textuals) - CAD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Disclosure of transactions between related parties [line items]
Compensation of key management and directors	$ 2,008,468	$ 1,223,773
Number of stock options issued to key management and directors	1,920,000	2,427,000
Stock options issued to key management and directors	$ 6,421,254	$ 6,620,570
Number of stock options exercised by key management and directors	699,999	25,000
Stock options exercised by key management and directors	$ 1,243,136	$ 88,376
Number of stock options forfeited by key management and directors	1,180,001
Stock options forfeited by key management and directors	$ 4,439,950
Management fees to related parties	320,000	378,674
Amount unpaid and included in accounts payable	26,667	26,667
Legal fees to related party	839,156	$ 549,387
Stenocare
Disclosure of transactions between related parties [line items]
Sale of cannabis extracts	170,336
O'Cannabis
Disclosure of transactions between related parties [line items]
Expenses incurred for services provided by related party	$ 46,443

INVESTMENTS (Details)

INVESTMENTS (Details) - CAD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Investments In Subsidiaries Joint Ventures And Associates [Line Items]
Investment Balance at December 31, 2017	$ 156,073
Investment and Advances	12,978,881
Share of Net Loss	(385,110)	$ (147,056)
Changes in Fair value	(2,087,912)
Investment Balance at December 31, 2018	10,661,932	156,073
CCTP
Investments In Subsidiaries Joint Ventures And Associates [Line Items]
Investment Balance at December 31, 2017	156,073
Investment and Advances	104,027
Share of Net Loss	(88,631)	(147,056)
Changes in Fair value	0
Investment Balance at December 31, 2018	171,469	156,073
GWAH
Investments In Subsidiaries Joint Ventures And Associates [Line Items]
Investment Balance at December 31, 2017	0
Investment and Advances	1,000,000
Share of Net Loss	(115,186)
Changes in Fair value	0
Investment Balance at December 31, 2018	884,814	0
O'Cannabis
Investments In Subsidiaries Joint Ventures And Associates [Line Items]
Investment Balance at December 31, 2017	0
Investment and Advances	500,000
Share of Net Loss	0
Changes in Fair value	0
Investment Balance at December 31, 2018	500,000	0
Stenocare
Investments In Subsidiaries Joint Ventures And Associates [Line Items]
Investment Balance at December 31, 2017	0
Investment and Advances	487,804
Share of Net Loss	(140,623)
Changes in Fair value	0
Investment Balance at December 31, 2018	347,181	0
NAC
Investments In Subsidiaries Joint Ventures And Associates [Line Items]
Investment Balance at December 31, 2017	0
Investment and Advances	5,000,000
Share of Net Loss	0
Changes in Fair value	(2,087,912)
Investment Balance at December 31, 2018	2,912,088	0
Cannatrek
Investments In Subsidiaries Joint Ventures And Associates [Line Items]
Investment Balance at December 31, 2017	0
Investment and Advances	5,887,050
Share of Net Loss	(40,670)
Changes in Fair value	0
Investment Balance at December 31, 2018	$ 5,846,380	$ 0

INVESTMENTS (Detail Textuals)

INVESTMENTS (Detail Textuals)	Oct. 15, 2018CAD ($)shares	Oct. 05, 2018CAD ($)	Aug. 14, 2018CAD ($)$ / sharesshares	Mar. 08, 2018	Jul. 15, 2015	Oct. 26, 2018CAD ($)Shareshares	Jun. 26, 2018$ / sharesshares	Dec. 31, 2018CAD ($)Share	Dec. 31, 2017CAD ($)Share	Dec. 20, 2018CAD ($)$ / sharesshares	Dec. 31, 2016CAD ($)Share
Investments In Subsidiaries Joint Ventures And Associates [Line Items]
Net loss and comprehensive loss after tax								$ (13,553,616)	$ 6,885,430
Company's share of net loss								(385,110)	(147,056)
Investments in subsidiaries, joint ventures and associates								$ 10,661,932	$ 156,073
Number of share options received | Share								4,114,563	3,526,000		0
Options outstanding, exercise price per share								$ 7.59	$ 3.45		$ 0
CCTP
Investments In Subsidiaries Joint Ventures And Associates [Line Items]
Proportion of ownership interest in joint venture					50.00%
Net loss and comprehensive loss after tax								(177,262)	(294,112)
Company's share of net loss								(88,631)	(147,056)
Investments accounted for using equity method								171,469	156,073
Investments in subsidiaries, joint ventures and associates								171,469	156,073
GWAH
Investments In Subsidiaries Joint Ventures And Associates [Line Items]
Proportion of ownership interest in joint venture							50.00%
Company's share of net loss								(115,186)
Number of warrant exercisable | shares							4,321,800			150,000
Number of common shares purchased | shares			769,231				4,321,800			150,000
Exercise price of warrants | $ / shares							$ 1.10			$ 2
Price per share of common stock purchased | $ / shares			$ 1.30
Amount of common stock purchased			$ 1,000,000
Investments in joint ventures										$ 750,000
Investments in subsidiaries, joint ventures and associates								884,814	0
O'Cannabis
Investments In Subsidiaries Joint Ventures And Associates [Line Items]
Proportion of ownership interest in joint venture		50.00%
Company's share of net loss								0
Investments in joint ventures		$ 500,000
Investments in subsidiaries, joint ventures and associates								500,000	0
Stenocare
Investments In Subsidiaries Joint Ventures And Associates [Line Items]
Net loss and comprehensive loss after tax								(740,120)
Company's share of net loss								(140,623)
Proportion of ownership interest in associate				25.00%
Decrease in ownership interest in associate				19.00%
Investments in subsidiaries, joint ventures and associates								347,181	0
Stenocare | Initial public offering
Investments In Subsidiaries Joint Ventures And Associates [Line Items]
Number of common shares purchased | shares	272,727
Amount of common stock purchased	$ 487,804
NAC
Investments In Subsidiaries Joint Ventures And Associates [Line Items]
Company's share of net loss								0
Investments in subsidiaries, joint ventures and associates						$ 5,000,000		2,912,088	0
Additional investment achieving specific performance targets						$ 10,000,000
Percentage of outstanding commom stock owned						3.00%
Cannatrek
Investments In Subsidiaries Joint Ventures And Associates [Line Items]
Company's share of net loss								(40,670)
Investments in subsidiaries, joint ventures and associates						$ 6,038,400		$ 5,846,380	$ 0
Number of shares invested in partnership | shares						6,400,000
Proportion of ownership interest in partnership						19.80%
Considerations paid allocated to common shares						$ 5,887,050
Considerations paid allocated to warrants						$ 151,350
Number of share options received | Share						6,400,000
Options outstanding, exercise price per share						$ 0.40

INCOME TAXES (Details)

INCOME TAXES (Details) - CAD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Major components of tax expense (income) [abstract]
Current	$ 0	$ 0
Deferred	1,433,000	0
Income tax provision	$ 1,433,000	$ 0

INCOME TAXES (Details 1)

INCOME TAXES (Details 1) - CAD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Major components of tax expense (income) [abstract]
(Loss) income before income taxes	$ (12,120,616)	$ 6,885,430
Combined statutory tax rate	26.50%	26.50%
Theoretical tax recovery	$ (3,211,963)	$ 1,824,639
Non-deductible expense:
Stock based compensation	2,134,960	612,330
Loss on equity accounted investments	102,054	38,970
Meals and entertainment	22,960	0
Changes in unrecognized deferred tax assets	808,625	(3,238,475)
Prior year adjustment	1,408,490	889,157
Other	167,874	(126,621)
Income tax expense	$ 1,433,000	$ 0

INCOME TAXES (Details 2)

INCOME TAXES (Details 2) - CAD ($)	Dec. 31, 2018	Dec. 31, 2017
Deferred tax assets
Non-capital losses carried forward	$ 4,702,681	$ 4,453,360
Property, plant and equipment	1,651,542	606,812
Investments	553,015	0
Share issuance costs	0	120,817
Deferred tax liabilities
Inventory	(6,074,373)	(5,180,989)
Biological assets	(2,265,865)	0
Net deferred tax liability	$ (1,433,000)	$ 0

INCOME TAXES (Details 3)

INCOME TAXES (Details 3) - CAD ($)	Dec. 31, 2018	Dec. 31, 2017
Major components of tax expense (income) [abstract]
Non-capital losses carried forward	$ 4,788,034	$ 208,267
Share issuance costs	6,424,709	0
Deferred tax assets not recognized	$ 11,212,743	$ 208,267

INCOME TAXES (Detail Textuals)

INCOME TAXES (Detail Textuals) - CAD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Major components of tax expense (income) [abstract]
Federal and provincial statutory income tax rate	26.50%	26.50%
Losses carried forward from prior years	$ 22,533,999

FINANCIAL INSTRUMENTS (Details)

FINANCIAL INSTRUMENTS (Details)	Dec. 31, 2018CAD ($)
Disclosure of detailed information about financial instruments [line items]
Contractual maturities of undiscounted cash flow	$ 26,854,944
Year 1
Disclosure of detailed information about financial instruments [line items]
Contractual maturities of undiscounted cash flow	16,797,068
Year 2-3
Disclosure of detailed information about financial instruments [line items]
Contractual maturities of undiscounted cash flow	9,857,876
Years 4 and after
Disclosure of detailed information about financial instruments [line items]
Contractual maturities of undiscounted cash flow	200,000
Accounts payable and accrued liabilities
Disclosure of detailed information about financial instruments [line items]
Contractual maturities of undiscounted cash flow	12,806,458
Accounts payable and accrued liabilities | Year 1
Disclosure of detailed information about financial instruments [line items]
Contractual maturities of undiscounted cash flow	12,806,458
Accounts payable and accrued liabilities | Year 2-3
Disclosure of detailed information about financial instruments [line items]
Contractual maturities of undiscounted cash flow	0
Accounts payable and accrued liabilities | Years 4 and after
Disclosure of detailed information about financial instruments [line items]
Contractual maturities of undiscounted cash flow	0
Mortgage
Disclosure of detailed information about financial instruments [line items]
Contractual maturities of undiscounted cash flow	13,248,486
Mortgage | Year 1
Disclosure of detailed information about financial instruments [line items]
Contractual maturities of undiscounted cash flow	3,790,610
Mortgage | Year 2-3
Disclosure of detailed information about financial instruments [line items]
Contractual maturities of undiscounted cash flow	9,457,876
Mortgage | Years 4 and after
Disclosure of detailed information about financial instruments [line items]
Contractual maturities of undiscounted cash flow	0
Promissory note
Disclosure of detailed information about financial instruments [line items]
Contractual maturities of undiscounted cash flow	800,000
Promissory note | Year 1
Disclosure of detailed information about financial instruments [line items]
Contractual maturities of undiscounted cash flow	200,000
Promissory note | Year 2-3
Disclosure of detailed information about financial instruments [line items]
Contractual maturities of undiscounted cash flow	400,000
Promissory note | Years 4 and after
Disclosure of detailed information about financial instruments [line items]
Contractual maturities of undiscounted cash flow	$ 200,000

FINANCIAL INSTRUMENTS (Details

FINANCIAL INSTRUMENTS (Details 1) - Mortgage	Dec. 31, 2018CAD ($)
Disclosure of detailed information about financial instruments [line items]
Mortgage	$ 13,248,486
Fair Value
Disclosure of detailed information about financial instruments [line items]
Mortgage	$ 13,518,501

FINANCIAL INSTRUMENTS (Detail T

FINANCIAL INSTRUMENTS (Detail Textuals) - CAD ($)		Dec. 31, 2018	Dec. 31, 2017
Disclosure of detailed information about financial instruments [abstract]
Short term investments	[1]	$ 63,023,908	$ 201,538
Current liabilities		16,797,068	6,779,997
Values for cash, short-term investments, Harmonized sales tax recoverable and accounts receivable		79,690,443	20,959,674
Values for cash and cash equivalents, short-term investments, restricted cash and accounts receivable		$ 78,298,333	$ 18,423,729
[1]	The investment is a one-year GIC, redeemable every 30 days, held with a large Canadian financial institution at fixed interest rate of 1.6%. The GIC is redeemable without penalty after 30 days.

REVENUE (Details)

REVENUE (Details) - CAD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Disclosure of disaggregation of revenue from contracts with customers [line items]
Total	$ 45,645,143	$ 20,697,764
Canadian Medical
Disclosure of disaggregation of revenue from contracts with customers [line items]
Total	35,270,446	20,697,764
Canadian Medical | Dried Cannabis
Disclosure of disaggregation of revenue from contracts with customers [line items]
Total	11,130,996	8,500,837
Canadian Medical | Extracts
Disclosure of disaggregation of revenue from contracts with customers [line items]
Total	22,936,664	11,291,635
Canadian Medical | Other
Disclosure of disaggregation of revenue from contracts with customers [line items]
Total	1,202,786	905,292
Wholesale
Disclosure of disaggregation of revenue from contracts with customers [line items]
Total	10,374,697	0
Wholesale | Dried Cannabis
Disclosure of disaggregation of revenue from contracts with customers [line items]
Total	8,060,510	0
Wholesale | Extracts
Disclosure of disaggregation of revenue from contracts with customers [line items]
Total	776,435	0
Wholesale | Other
Disclosure of disaggregation of revenue from contracts with customers [line items]
Total	$ 1,537,752	$ 0